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ABSTRACT
The structure and function relationship between melanocortin-2 receptor (MC2R)
and ACTH are the most complicated in melanocortin receptor gene family. A
comparative study on the activation of human and rainbow trout MC2R will provide a
useful model system for understanding how ACTH emerged as the sole ligand for the
MC2R of bony vertebrates. This dissertation will discuss how studies utilizing analogs of
hACTH(1-24) have revealed two critical amino acid motifs in this ligand (HFRW and
KKRRP) which are required for the activation of MC2R. In addition, the KKRRP motif
functioned as the unique binding site for MC2R that directly contributes to the ligand
selectivity feature, as revealed from studies on an ACTH antagonist which exclusively
targets MC2R. Finally, based on our model for the interaction of ACTH and MC2R, the
amino acid residues within TM4, EC2, and TM5 domains responsible for ACTH ligand
selectivity will be evaluated by site-directed mutagenesis studies.
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INTRODUCTION

Stress and Hypothalamus-pituitary-adrenal (HPA) Axis
The ability to evoke stress response to physiological and psychological stimuli is
necessary to increase the survival rate of organisms. In mammals, common stress
responses include neuroendocrine response and autonomic response, known as the twopronged physiological defense mechanism (Pecoraro et al., 2006). The neuroendocrine
stress response is regulated by hypothalamus-pituitary-adrenal (HPA) axis (Figure 1). In
this circuit, stressful stimuli cause corticotropin releasing hormone (CRH) to be released
from hypothalamic paraventricular nucleus (PVN) to pituitary portal circulation, and then
stimulate the secretion of adrenocorticotropic hormone (ACTH) from corticotropes in the
anterior pituitary. The melanocortin peptide ACTH then induces the production of
glucocorticoids in the adrenal cortex, via the activation of the ACTH receptor or the
melanocortin 2 receptor (Chan et al., 2011). Consequently, glucocorticoids launch both
rapid and prolonged effects on its target cells throughout the system, influencing
metabolism, feeding behavior, and energy expenditure (Pecoraro et al., 2006; Mormede
et al., 2011). Meanwhile, the HPA axis is under the negative feedback regulation of the
circulating glucocorticoids at the level of the hippocampus, hypothalamus and pituitary
(Jacobson and Sapolsky, 1991; Keller-Wood and Dallman, 1984; Cole et al., 2000).
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In teleosts, steroidogenesis occurs in the interrenal tissues of the head kidney
instead of adrenal gland. Therefore, the hypothalamus-pituitary-interrenal (HPI) axis
mediates their neuroendocrine stress response. CRH neurons whose cell bodies are
located at nucleus preopticus and nucleus lateralis tuberalis regions of the hypothalamus
directly synapse to pituitary adrenocorticotropic cells (Thomas, 2008). As the result of
CRH stimulation, ACTH is released from the pituitary to the systemic circulation.
Thereafter, ACTH targets the melanocortin 2 receptors (MC2R) expressed on interrenal
steroidogenic cells, and activates steroidogenesis which could be sustained for several
hours in some fish species (Liu et al., 2006; Mommsen et al., 1999).

Melanocortin Receptor Family
Melanocortin receptors (MCRs) are G protein-coupled receptors (GPCRs), in the
rhodopsin/β adrenergic like family A. GPCRs are single chain polypeptides forming
seven membrane spanning alpha-helical regions that are linked by extracellular and
intracellular domains (Devi, 2005). Conserved structural features of GPCRs found in
MCRs include consensus N-linked glycosylation sites near the extracellular amino
terminus and a palmitoylation site in the intracellular C-terminus (Yang, 2011; Gantz and
Fong, 2003). Melanocortin receptors have short N- and C-terminus and a small second
extracellular loop, therefore, they are the smallest GPCRs known. So far, five
melanocortin receptors have been identified in vertebrates (Cone, 2006). Their
physiological functions and ligand preference are summarized in Table 1.
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MC1R: Human MC1R (317 amino acids) is predominantly expressed in
melanocytes and melanoma cells, and it couples to the cyclic adenosine monophosphate
(cAMP) signaling pathway (Chhajlani and Wikberg, 1992). Because MC1R mediates
pigmentation, it is a major determinant of skin phototype and sensitivity to ultraviolet
(UV) light induced skin damage (García-Borrón et al., 2005). In addition, MC1R is also
found in fibroblasts, endothelial cells, monocytes, dendritic cells, neutrophils,
granulocytes, osteoclasts, Leydig and lutein cells etc., suggesting its wide spectrum of
physiological functions, such as anti-inflammatory and anti-pyretic actions (GarcíaBorrón et al., 2005).
MC2R: MC2R (297 amino acids in humans) is also known as the ACTH receptor,
since ACTH is the only ligand for this receptor (Table 1). As one of the key components
of HPA/I axis, MC2R mediates the expression of steroidogenic enzymes via cAMP and
PKA signaling pathway. As a result of MC2R activation, cortisol (the glucocorticoid in
human and most teleosts) is secreted and elicit stress response on its target
tissues. Mutations of MC2R account for approximately 25% of the cases of an autosomal
recessive disease, familial glucocorticoid deficiency (FGD) (Chan et al., 2008). Other
than the zona faciculata of the adrenal cortex, MC2R is also expressed in skin (Slominski
et al., 1996) and adipocytes (Boston and Cone, 1996).
MC3R: Human MC3R is a 361 amino acid protein, which is mainly expressed in
hypothalamic and limbic regions of brain (Roselli-Rehfuss et al., 1993). Mc3r-/- mice
showed accelerated weight gain and accumulation of extra fat mass, indicating its role in
peripheral metabolism and energy balancing (Butler, 2006). Moreover, MC3R is the
3

only receptor in the melanocortin receptor family that can activate both cAMP, inositol
triphosphate (IP3) and Ca2+ signaling pathways (Konda et al., 1994; Wachira et al., 2003).
Expression of MC3R is also identified in the placenta, stomach and pancreas (Gantz et al.,
1993).
MC4R: Another receptor in this family that regulates energy homeostasis is
MC4R (322 amino acids in humans). It is predominantly expressed in the brain,
autonomic nervous system and spinal cord (Mountjoy and Wild, 1998). Compared to
MC3R knockout mice, the obesity syndrome was far more sever in MC4R-/- mice, and is
associated with hyperphagia, hyperinsulinemia, hyperleptinemia (Huszar et al., 1997). In
addition to energy metabolism regulation, MC4R is also found to be involved in erectile
dysfunction (Martin and MacIntyre, 2004) and pain (Starowicz and Przewlocka,
2003). MC4R transduces a signal by coupling to the heterotrimeric Gs protein and
activating adenylate cyclase (Gantz et al., 1993).
MC5R: MC5R (325 amino acids) is the last melanocortin receptor to be cloned,
and is expressed in skin, adrenal gland, adipose tissue, kidney, lymph nodes, liver,
skeletal muscle and exocrine glands (Cooray and Clark, 2011). MC5R is involved in the
production of sebaceous lipids (Chen et al., 1997), protein and tear secretion by the
lacrimal gland (Entwistle et al., 1990). Activation of MC5R leads to the increase of
intracellular cAMP and Ca2+ (Hoogduijn et al., 2002).
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Melanocortins
The natural ligands of melanocortin receptors are melanocortin stimulating
hormones (MSHs) (α-MSH, β-MSH and γ-MSH) and ACTH, which are all derived from
a common precursor pro-opiomelanocortin (POMC). In vertebrates, the POMC gene is
expressed in hypothalamic neurons, anterior and intermediate pituitary, immune system
and skin (Bertagna, 1994). Depending on the type of tissue, there are two outcomes in the
posttranslational processing of POMC: (1) in the corticotropes of the anterior pituitary,
POMC is endoproteolytically cleaved by proprotein convertase 1/3 (PC1/3). As a result,
the major product is ACTH; (2) in the melanotropes of intermediate pituitary,
melanocytes in skin, and certain neurons, PC1/3 and proprotein convertase 2 (PC2) work
together to produce α-MSH, β-MSH, and γ-MSH (Figure 2A). Other end-products
cleaved from the same precursor include CLIP, β-lipotropin (LPH), γ-LPH, and βendorphin (Eipper and Mains, 1980).
Although individual preference does exist, MC1R, MC3R, MC4R and MC5R can
be activated by any forms of the melanocortin peptides (see Table 1). Hence, people have
identified a common sequence of melanocortins known as the “HFRW” motif (shown in
Figure 2B) as the binding and activation site for these receptors (Schwyer, 1977).
However, “HFRW” motif is not sufficient to allow MSHs to activate MC2R, since
ACTH is the only ligand for this receptor. Because α-MSH [N-acetyl-ACTH(1-13)amide]
is cleaved from ACTH by PC2 but unable to bind to MC2R. It appears that MC2R
requires an additional binding site on the C-terminus of ACTH, which is not present in
MSHs (Veo et al., 2011).
5

Melanocortin 2 Receptor Accessory Protein (MRAP)
While the heterologous expression of MC1R, MC3R, MC4R and MC5R has been
successfully achieved in mammalian cell lines, studies found that only mammalian
MC2R could not be functionally expressed in heterologous cells lines unless those cell
lines were derived from the adrenal cortex (Forti et al., 2006; Rached et al., 2005). In
addition, it was reported that a subset of patients exhibiting FGD syndrome had
functional MC2 receptors, but were resistant to ACTH treatment (Metherell et al., 2005).
Collectively, these observations led to the discovery that adrenal cortical cells express
melanocortin receptor accessory proteins (Metherell et al., 2005).
In the genomes of many vertebrates, there are two paralogous mrap genes (mrap1
and mrap2) (Hinkle and Sebag, 2009; Webb and Clark, 2010). MRAPs are single chain
polypeptides with a single membrane spanning domain. Both MRAP1 and MRAP2 can
form antiparallel homodimers in the ER (Hinkle and Sebag, 2009), and both types of
homodimers will couple to MC2R in the ER and facilitate the trafficking of mammalian
MC2Rs to the plasma membrane (Figure 3). However, only MRAP1/MC2R complexes
on the plasma membrane can be efficiently activated by ACTH, whereas the efficacy of
ACTH activation is greatly diminished for MRAP2/MC2R complexes (Hinkle and Sebag,
2009; Webb and Clark, 2010). Furthermore, the role of MRAP1 in the trafficking and
activation of MC2R is not limited to mammals, but also has been confirmed in orthologs
of zebra fish (Danio rerio), rainbow trout (Oncorhynchus mykiss), and a frog (Xenopus
tropicalis) (Agulleiro et al., 2010), suggesting that all vertebrate MC2Rs require MRAP1
for functional expression (Liang et al., 2011).
6

Evolution of MCR and MRAP
Five melanocortin receptor coding gene were found in the genomes of tetrapods,
whereas none was identified in non-chordate metazoans (Vastermark and Schioth, 2011),
indicating the evolution of melanocortin receptor gene family appeared during the
evolution of phylum Chordata. Thus, the evolution of this gene family would have been
influenced by the two generally accepted genome duplication events (2R hypothesis) that
occurred during the radiation of this phylum (Ohno et al., 1968; Lundin, 1993) and then
at least one localized gene duplication event (Schioth et al., 2005). Using the evolution of
HOX genes as a model (Holland et al., 1994), the generally accepted scenario (shown in
Figure 4A) is that the ancestral gene of MCR undergo first duplication event and yield
first two paralogous genes (MCa and MCb receptors) in agnathan vertebrates, and then the
second duplication event led to four paralogous genes in the ancestral gnathostomes
(Vastermark and Schioth, 2011). The fifth paralogous melanocortin receptor coding gene
that is present in the genomes of teleost Danio rerio (Logan et al., 2003), and the
tetrapods Xenopus tropicalis and Mus musculus (Cone, 2006) provides the evidence for
the localized gene duplication in the early radiation of the gnathostomes (Schioth et al.,
2005).
In the search for MRAP orthologs, it was noticed that the ortholog of MRAP2 but
not MRAP1 is present in the genomes of sea lamprey and elephant shark, whereas Fugu
(Takifugu rubripes) has both paralogous genes (Vastermark and Schioth, 2011). As a
result, mrap2 gene is considered as the ancestral gene of MRAP, and it appeared
relatively early in the evolution of the vertebrates, but prior to the second genome
7

duplication event that occurred with the emergence of the gnathostomes (Ohno et al.,
1968). At a later stage, the timeline of the appearance of mrap1 gene overlaps with
MC2R orthologs (Figure 4B). Phylogenetic and functional expression analysis suggests
that the co-evolution of MRAP1/MC2R has diverged to yield a bony fish trend and a
tetrapod trend with respect to the interaction between MC2R and MRAP1during the
radiation of the vertebrates (Liang et al., 2011).

Specific Aims:
Working from these observations, this study had two objectives. The first
objective was to answer the question: which regions in ACTH are responsible for the
MC2R activation? We hypothesized that three zones of ACTH were involved in the
MC2R activation. ACTH(1-24) consists of twenty-four residues of ACTH(1-39) that are
conserved across most species and are capable of activating MC2R, and was used as the
wild type ligand (Figure 2)(Costa et al., 2004). The first zone in ACTH(1-24), named
Zone A for the purposes of the experiment, is where residues 6-9, HFRW, are found.
This sequence appears in the sequences of α- and β-MSH and is necessary for the
activation of the other MCRs (Cone, 2006). The second region of interest consisted of
residues 10-14, GKPVG (Glycine-Lysine-Proline-Valine-Glycine), and was named Zone
B. The third region of interest consisted of residues 15-19, KKRRP (Lysine-LysineArginine-Arginine-Proline), and was dubbed Zone C (Figure 2). The hypothesized
mechanism of activation of MC2R by ACTH(1-24)is viewed as a multi-step process.
The C-terminal region, Zone C, of ACTH(1-24) would make contact with MC2R at a site
different from the HFRW-binding site, which would cause the opening of the HFRW8

binding site. This event would allow the HFRW motif on the ligand to bind and cause
the subsequent conformational changes to the receptor and activation of the G-protein
(Baron et al, 2009). The approach to validate this hypothesis was to test the activation of
analogs of ACTH in Zones A, B, and C of wild type MC2R.
The second objective was to answer the question: which regions of MC2R are
responsible for ACTH ligand selectivity (Figure 5)? The hypothesized model entails a
docking pocket for the C-terminal residues of ACTH(1-24), Zone C, and a separate
binding site for HFRW, Zone A, with a central adaptor region of ACTH, Zone B, to
accommodate a better fit into the two pockets. The second docking pocket was
hypothesized to be created by transmembrane regions 4 and 5 and extracellular loop 2.
Individual residues in TM4, EC2, and TM5 were replaced with an alanine residue and
each single mutant construct was stimulated with ACTH in a dose-dependent manner.
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Figure 1. Hypothalamus-Pituitary-Adrenal axis in mammals (Adapted from Lightman
and Conway-Campbell, 2010)
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Table 1. Localization, physiological functions and ligand preference of melanocortin
receptors 1 through 5 in mammals (Adapted from Cone, 2006).
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A.

B.

[ A][ B ][ C ]

Figure 2. Melanocortin peptides in humans. A) Selective processing of POMC by
enzymes PC1/3, and PC2. Some KR cleavage sites are suspected to be selected by PC2
B) Alignment of amino acid sequences of melanocortin peptides.
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Figure 3. Melanocortin 2 Receptor Accessory Protein (MRAP) forms antiparallel
homodimer in ER, and then facilitates the trafficking of MC2R to plasma membrane
(Adapted from Webb and Clark, 2010).
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A.

B.

Figure 4. Modeling the evolution of melanocortin receptors in phylum chordata. A)
Hypothetical scheme for the radiation of the melanocortin receptors during the evolution
of the chordates. Ancestral MCR—predicted MCR gene in protochordates. MCR’ and
MCR’’—predicted MCR genes formed after the first genome duplication event.
MC5R/MC2R—predicted ancestral gene for MC5R and MC2R. B) Phylogeny of
melanocortin receptors in extant vertebrates. (MCR) refers to the predicted ancestral
MCR gene in protochordates. [] indicates some genes that is predicted to have been
secondarily lost in some species. * indicates MC2R in these species that can only be
activated by ACTH. (Adapted from Baron et al., 2009).
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METHODS AND MATERIALS

Tissue Culture
Chinese Hamster Ovary (CHO) cells (obtained from ATCC, VA) were used in
all experiments performed. Cells were grown in Kaighn’s Modification of Ham’s F12K
media (ATCC) supplemented with 10% fetal bovine serum, 100unit/ml penicillin,
100µg/ml streptomycin, 100µg/ml normacin, and maintained in a humidified incubator
with 95% air and 5% CO at 37°C. When reaching 80% confluence, CHO cells were
2

split into subcultures using 0.05% trypsin/0.53mM EDTA.

DNA Constructs
Human MC2R (accession no. AA067714.1) and rainbow trout MC2R (accession
no. EU119870.1), were synthesized by GenScript (Piscataway, NJ) with an N-terminal
V-5 epitope tag and inserted into a pcDNA3.1+ vector. Mouse (Mus musculus) MRAP1
(accession no. NM_029844), zebrafish (Danio rerio) MRAP1(accession no. XR_117835),
were individually synthesized by GenScript with an N-terminal FLAG epitope tag and
were separately inserted into pcDNA3.1+ vectors. cAMP reporter construct CRE-Luc
(Chepurny and Holz, 2007) was provided by Dr. Patricia Hinkle (University of
Rochester, NY). All DNA constructs were inserted in pcDNA3.1+ vector individually.
15

Mutations were introduced to receptor constructs by site-directed mutagenesis with
individual alanine substitutions (Performed by GenScript, Piscataway, NJ). Positions in
hMCc2R and rtMC2R examined by this study were shown in Figure 5.

ACTH Analog Peptides
Human adrenocorticotropic hormone ACTH(1-24) and NDP-α MSH was
purchased from Sigma-Aldrich Inc.(St. Louis, MO). The rest of hACTH(1-24) analogs
including alanine substitutions and truncated peptides were synthesized by New England
Peptide Inc. (Boston, MA). The amino acid sequences of hACTH(1-24) analogs used in
this study are listed in Table 2.

Immunocytochemistry
CHO cells were seeded in 8-well chamber slides (2.5×104 cells/well), and after 24
hours, transfected with 1µg of DNA construct using lipofectamine 2000 (Invitrogen,
Carlsbad, CA) and OptiMEM (Mediatech Inc, Herndon, VA). Cells were allowed to
express the receptors/MRAPs for 24 hours and fixed with 4% PFA for 15 minutes,
washed, and then half of the wells were permeablized with 0.3% triton X-100 for 10
minutes. Primary antibodies (mouse anti V5 and/or rabbit anti FLAG, 1:500 dilution)
were applied to the cells for 1 hour at 37°C. After three washes with PBS, cells were
incubated with secondary antibodies (donkey anti mouse conjugated with Alexa388
and/or donkey anti rabbit conjugated with Alexa555, 1:800 dilution) for 45 minutes at
37°C. After three washes with PBS, chambers were removed from slides. Coverslips
16

were mounted with Vecta-shield (Vector Laboratories Inc, Burlingame, CA), and nuclei
were stained with DAPI (blue). Slides were imaged using 100X oil immersion objective
with a fluorescent Zeiss Axioplan 2 microscope equipped with Hamamatsu digital
camera. All images were analyzed with SlideBook (www.slidebook .com) software.

cAMP Reporter Assay
For the cAMP assay, 2.5×106 CHO cells were cotransfected with MC2R, MRAP,
and CRE-Luc (Chepurny and Holz, 2007) DNA constructs (2µg each) using Amaxa Cell
Line Nucleofector II system (Lonza, MD) with solution T and program U-23. After 10minute recovery, cells were then seeded in white 96-well plate with a final density of
1×105cells/well. 48 hours after transfection, cells were stimulated with ACTH analogs
diluted within serum-free CHO media for 4 hours. Analogs were tested at doses ranging
from 10-6M to 10-14 M, and each dose was tested in triplicate against a wild type
ACTH(1-24) control. Then stimulating media were removed, Luciferase substrate reagent
Bright GLO (Promega, WI) was applied to the wells, and incubated at room temperature
for 5 mins. Luminescence was measured by Bio-Tek Synergy HT plate reader (Winooski,
VT). To determine the basal levels of cAMP production, transfected CHO cells
stimulated with vehicle were measured along with each experiment group individually.
Luminescence readings were first subtracted by their basal activity and then fit to
Michaelis-Menton equation to obtain EC50 values. Data were analyzed using
Kaleidograph software (www.synergy.com)

17

cAMP Enzyme Immunoassay
Cells transiently transfected with MC2R and MRAP (Amaxa nucleofection kit T)
were plated in 6-well plates at a density of 3×105 cells/well and allowed to recover from
transfection for 48 hours. ACTH analogs were diluted as needed in standard extracellular
solution (10mM D-glucose, 2mM KCl, 1mM MgCl2, 5mM CaCl2, 140mM NaCl, 10mM
HEPES and 0.5% BSA). 1mM 3-Isobutyl-1-methylxanthine (IBMX) was used in
solutions to prevent the degradation of intracellular cAMP from phosphodiesterase.
Analogs were tested at concentrations ranging from 10-6M to 10-10 M, and each dose was
tested in triplicate against a wild type ACTH(1-24) control. After 15-minute incubation at
37°C, analogs were removed from the wells, and the cells were lysed and collected within
0.1M HCl after well scraping. Lysate was centrifuged at 4.5RCF for 5 minutes, and the
supernatant containing cAMP was assayed immediately using a direct cAMP EIA kit
(Assay Design, Ann Arbor, MI) and measured with Bio-tek Syngerty HT plate reader
(Winooski, VT).

Radioligand Binding Assay
CHO Cells transiently transfected with MC2R and MRAP (Amaxa nucleofection
kit T) were plated in 12-well plates at a density of 2×105 cells/well. Assay was performed
after for 48 hours after transfection for cell recovery and receptor expression. To stabilize
these cells, binding buffer (10mM Glucose, 1mM MgCl2, 10mMHEPS, 5mM CaCl2,
140mM NaCl, 2mM KCl, with 0.1% BSA) was applied to each well, incubated for 20
min at 37°C and then removed. 1×105 cpm ACTH(1-39)Tyr23I125(Perkin Elmer,
18

Waltham, MA) was used in combination of non-radiolabeled ACTH analogs within
binding buffer. After 1 hour incubation at 37°C, binding reaction was terminated by
removing the binding buffer and followed by three washes with cold PBS on ice. Cells
were then solubilized with 0.1% SDS for 30 minutes at room temperature. After well
scraped, cell lysate was collected and the radioactivity was quantified by a gamma
counter.

Cell Surface ELISA
CHO cells were seeded in 24-well plates (5×104 cells/well), and after 24 hours,
transfected with 250ng of each DNA construct using lipofectamine 2000 (Invitrogen,
CA). Cells were allowed to express the receptors for 24 hours and fixed with 4% PFA.
0.3% triton X-100 was applied to half of the wells to permeablize the cells. Then
blocking buffer (5% dry milk in PBS supplemented with 10% FBS and 5% normal goat
serum) was applied to the well overnight at 4°C. cells were incubated with primary
antibodies mouse anti V5 and/or rabbit anti FLAG(1:2000) for 1 hour at 37°C, washed
three times for 5 minutes, followed with secondary antibody goat anti-mouse conjugated
with HRP (1:2000) for 45mins at 37°C. Wells were again washed three time for 5
minutes, and allowed to dry before adding 200 µL TMB (Invitrogen, MD) and allowed to
incubate for 10 minutes at room temperature. The reaction was halted by adding 200 µL
1N HCl and gently swirling. 300 µL from each well was transferred to a 96-well plate
and read immediately at absorption 450nm by Bio-Tek Synergy HT plate reader
(Winooski, VT). All experiments were performed in triplicates with a GFP transfected
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control. Data were normalized to GFP control and analyzed using Student’s t-test for
equal variance with Kaleidograph software (www.synergy.com).

Statistical Analysis
Data points are expressed as the mean with standard error of values obtained from
experiments which were performed in triplicates. Differences between experimental
treatments with corresponding controls were determined using unpaired two-tailed
Student’s t-test for equal variance. Significance was set at P≤0.05.
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A. hMC2R

B. rtMC2R

Figure 5. Two-dimensional structures of the hsMC2R (A) and rtMC2R (B). Mutant
positions examined in this study are highlighted in grey.
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Table 2. hACTH(1-24) analogs used in this study. Alanine substitutions in amino acid
sequences are underlined.
ACTH Analogs

Amino Acid Sequences

Wild Type

ACTH(1-24)

SYSMEHFRWGKPVGKKRRPVKVYP

Zone A

A4/HFRW
HFAW
HARW
AFRW
HFRA

SYSMEAAAAGKPVGKKRRPVKVYP
SYSMEHFAWGKPVGKKRRPVKVYP
SYSMEHARWGKPVGKKRRPVKVYP
SYSMEAFRWGKPVGKKRRPVKVYP
SYSMEHFRAGKPVGKKRRPVKVYP

Zone B

A10-14
A10/14
KP
P12
ACTH(1-22)
ACTH(1-21)

SYSMEHFRWAAAAAKKRRPVKVYP
SYSMEHFRWAKPVAKKRRPVKYVP
SYSMEHFRWGAAVGKKRRPVKVYP
SYSMEHFRWGKAVGKKRRPVKVYP
SYSMEHFRW-KPV-KKRRPVKVYP
SYSMEHFRWG---GKKRRPVKVYP

Zone C

A5/Tetra
AARRP
KKAAA
AAW

SYSMEHFRWGKPVGAAAAAVKVYP
SYSMEHFRWGKPVGAARRPVKVYP
SYSMEHFRWGKPVGKKAAAVKVYP
SYSMEHFRWGKPVGKRAAWVKVYP

Zone D

A20-23
V20
K21
V22
Y23
P24

SYSMEHFRWGKPVGKKRRPAAAAP
SYSMEHFRWGKPVGKKRRPAKVYP
SYSMEHFRWGKPVGKKRRPVAVYP
SYSMEHFRWGKPVGKKRRPVKAYP
SYSMEHFRWGKPVGKKRRPVKVAP
SYSMEHFRWGKPVGKKRRPVKVYA

α-MSH
Analogs

NDP-αMSH
ACTH(4-10)

C-terminal
Analogs

KPV
Ac-GKKRRP
Ac-KKRRP
KKRRP
KKRRPAs
RRP
PVK

Ac-SYSMEHFRWGKPV
MEHFRWG
KPVGKKRRPVKVYP
Ac-GKKRRPVKVYP
Ac-KKRRPVKVYP
KKRRPVKVYP
KKRRPAAAAA
RRPVKVYP
PVKVYP
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CHAPTER ONE
Ligand Selectivity Properties of Human Melanocortin-2 Receptor

The ligand selectivity feature makes melanocortin 2 receptor a very special
member in its gene family. Unlike other melanocortin receptors, mammalian MC2Rs, and
perhaps all bony vertebrate MC2Rs, can only be activated by ACTH, but not by any
MSHs (Cone, 2006). This chapter will focus on identifying the critical amino acid motifs
that are responsible for hMC2R ligand selectivity by analyzing various regions of
hACTH sequence.
As noted in the Introduction, the full length of ACTH peptide in most species of
vertebrates is 39 amino acid residues (Dores and Lecaude, 2005). However, earlier
studies reviewed by Schwyzer (1977) indicated that the functional domain required for
activating the adrenal “ACTH” receptor was located within the first 24 residues of this
hormone. Hence, in this study, hACTH(1-24) was used in all the experiments
representing mammalian adrenocorticotropic hormone. As summarized by Schwyzer
(1977), truncated analog studies have uncovered two functional motifs within ACTH: the
HFRW motif and the KKRR motif, which will be reevaluated in this study using alanine
substitution analogs in order to retain the secondary structure of ACTH as much as
possible.
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Since the HFRW motif is present in all of the melanocortin peptides (Nakanishi et
al., 1979), the key to understanding the ligand selectivity of an MC2R would appear to lie
in residues 14 to 24 in the sequence of ACTH(1-24). As a result, the importance of the Cterminal domain will be carefully examined utilizing alanine substitution analogs of
hACTH(1-24). Based on the sequence of interest, ACTH analogs examined in this
chapter were grouped into four categories (Table 2): (1) Zone A analogs—H6F7R8W9; (2)
Zone B analogs—G10K11P12V13G14; (3) Zone C analogs—K15K16R17R18P19; (4) Zone D
analogs—V20K21V22Y23P24.

Results

Ligand Selectivity of hMC2R
Zone A Analogs
To determine the importance of each amino acid residue in HFRW motif, we
designed and examined five Zone A analogs (See sequences in table 2) on CHO cells
transiently transfected with hMC2R and mMRAP1 (Figure 6A). Consistent with previous
studies, A4 analog which has four alanine substitutions at HFRW motif cannot stimulate
the hMC2R activation. In order to test how these positions of this region contribute to the
activation of receptor, analog AFRW, HARW, HRAW, and HFRA was applied
individually to stimulate the transfected cells. Analog HFRA was unable to activate
hMC2R in the same manner of A4 analog, indicating that the tryptophan residue plays
an essential role in this motif. Moreover, although analog AFRW, HARW, and HRAW
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were able to activate hMC2R, the shifts in EC50 values of their activation curves were 8fold, 8000-fold, and 440-fold as compared to ACTH(1-24) (Table 3). Student t-test
analysis showed that alanine substitution on phenylalanine (HARW) and arginine
(HFAW) significantly diminished receptor activation. As a result, the order of the
importance of these positions is W9>F7>R8>H6.

Zone B Analogs
The region between HFRW and KKRRP was also first examined using four
ACTH(1-24) analogs with alanine substitutions at G10K11P12V13G14, G10G14, K11P12, and
P12 (Analog A10-14, AKPVA, GAAVG, and GKAVG in Table 2) on transfected CHO
cells. Analog A10-14 showed significantly reduced activation activity with a 900-fold
increase in the EC50 value, whereas other analogs substituted with single or double
alanines in this region did not show any obvious decline as compared to ACTH(1-24)
(Figure 6B and Table 3). Nevertheless, when we tested two truncated analogs ACTH(121) and ACTH(1-22) that skip position G10G14 or K11P12V13 within this domain,
ACTH(1-21) complete lost the stimulatory effect to hMC2R while the ACTH(1-22)
response was undetectable until 10-7M (Figure 6C).

Zone C Analogs
Three ACTH analogs with alanine substitutions (See sequences in Table 2) were
synthesized in order to evaluate the importance of KKRRP motif in terms of hMC2R
activation on transfected CHO cells. Replacing KKRRP with five alanines (A5 analog)
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greatly reduced the activation of receptor by 3000-fold shifting in EC50 (Figure 6D and
Table 3). Further, position K15K16 and R17R18P19 were tested separately using analog
AARRP and KKAAA. The EC50 values of both analogs were significantly increased as
compared to ACTH(1-24), while analog KKAAA is a less potent ligand compare with
AARRP (Table 3).

Zone D Analogs
Albeit alanine substitution at KKRRP motif introduced a significant right shift in
ACTH dose response curve, note that it was still able to stimulate a weak response at
concentration of 10-7M (Figure 6B). This observation raise the possibility that the
subsequent sequence V20K21V22Y23P24 may play a role in facilitating ACTH(1-24)
binding to the receptor. To test this hypothesis, six Zone D analogs (A20-23, V20, K21,
V22, Y23 and P24) were examined on hMC2R (see sequences in Table 2), whereas all of
these analogs did not affect the activation curve as compared to ACTH(1-24) (Figure 7).

Binding Affinity Analysis
In addition to receptor activation assay, analogs from each region that showed
great reduction in activation activities were further examined with radioligand binding
assay (Figure 8A). A right shift in binding curve showed in all three analogs (A4, A5 and
A10-14), while only the Ki value of analog A5 was significantly greater as compared to
ACTH(1-24) (P<0.05).
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Discussion

The HFRW motif is present in all of the melanocortins (Nakanishi et al., 1979).
N-terminally truncated analogs of mammalian ACTH(1-24) in which this region of the
polypeptide has been eliminated lack the ability to activate any melanocortin receptor
(Eberle and Schwyzer, 1975; Schwyzer, 1977). Hence, the HFRW motif has been
identified as the core sequence of all melanocortin peptides, and consistently in this
study, alanine substitutions in this motif (A4 analog) completely abolished the activation
of hMC2R as indicated in Figure 6A. However, not all four positions in this motif are
equally important for the activation of hMC2R. It appears that tryptophan9 plays a
prominent role in the functioning of this motif, since alanine substitution on this position
caused a complete loss in activation as analog A4 did. Assuming that the HFRW motif in
ACTH(1-24) also forms a reverse β-turn as observed for α-MSH (Ying et al., 2003), the
backbone structure held by the stacking of histidine6 and phenylalanine7 aromatic rings
would still be intact in analog HFRA. Thus, the side chain of tryptophan9 was probably
interacting with certain sites of hMC2R which is critical for activation. Other than
tryptophan9 and phenylalanine7 which is the central residue in the reverse β-turn, alanine
substitution at arginine8 greatly affected receptor activation as well. As reported by Lee
and colleagues (1998), the same arginine8 in α-MSH analog was responsible for the
electrostatic interactions between the ligand and the complementary residues of the
receptors (e.g., the TM3 residue D122 in hMC4R). When Zone A analogs were applied to
human MC4R, similar effects showed in the activation curves (Figure 8B). The activation
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of hMC4R required the presence of tryptophan9, which appears to be the most significant
residue in HFRW motif as well. However, every residue in this motif was important for
hMC4R activation, and the order of importance of other residues was:
arginine8>phenylalanine7>histadine6 (Table 4). Based on these observations, it is
reasonable to postulate that the HFRW motif is an important binding site for hMC2R, but
at least in terms of activation it is slightly different with the mode of hMC4R. According
to Pogozheva et al. (2005), of the twelve residues in TM2, TM3, TM6 and TM7 of
hMC4R that are involved in the binding of HFRW motif, ten amino acids are conserved
residues in melanocortin receptors (Figure 9). Six amino acids are identical in all five
melanocortin receptors, while four amino acids (F129 in TM3, V262 and V265 in TM6,
and G288 in TM7) are unique in MC2R. The differences in residues may lead to a
boarder HFRW binding site for MC4R, hence, alanine substitution at HFRW motif had a
greater effect on MC2R activation as compared to MC2R.
As reviewed by Schwyzer (1977), the shortest analog of ACTH(1-24) that still
retains some level of biological activity is ACTH(1-16), and conversely analogs longer
than ACTH(1-16) are progressively stronger agonists. Costa et al. (2004) conducted a
series of studies that focused on residues in the motif KKRRP in the sequence of
hACTH(1-24). Alanine substitutions at any of these sites lowered the biological activity
of the ACTH(1-24) analog with varying degrees of efficacy. Collectively, the
experiments using C-terminally modified analogs of ACTH(1-24) point to the KKRRP
motif in mammalian ACTH(1-24) as an important region for the activation of MC2R. In
agreement with this hypothesis, the replacement of the KKRRP motif in hACTH(1-24)
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with alanines (A5 analog) produced an analog with a greatly diminished capacity for
activating MC2R (Figure 6B). This reduction in activation was probably resulting from
the significant drop of ligand binding affinity (Figure 8A). With a closer look in KKRRP
motif, the R17R18P19motif appears to be more critical than the K15K16 motif (Figure 6B
and Table 3). Although analog A5 introduced a right shift in activation curve, it was still
able to bind to and stimulate hMC2R at concentrations higher than 10-7M (Figure 6B),
implying the involvement of the subsequent sequence VKVYP at C-terminal of ACTH(124). Albeit alanine substitution at this domain didn’t affect hMC2R activation curves
(Figure 7), truncated analog KKRRP partially lost its competitive ability as compared to
KKRRP analog (See Chapter Two Figure 12B), probably due to a reduction of binding
affinity. Taken together, these observations supported the hypothesis that KKRRP motif
functions as a secondary binding site of ACTH for the activation of hMC2R.
Accepting the premise that there is an HFRW binding site as well as a KKRRP
binding site on hMC2R, we next wished to address the question of the relative distance
between these two binding sites. As indicated in Figure 7, substitution with five alanines
at this region greatly reduced activation activities of hMC2R, while the truncated Zone B
analog, neither ACTH(1-21) nor ACTH(1-22), was able to stimulate this receptor. Based
on these observations, it seems that the G10K11P12V13G14 sequence, especially the
distance between HFRW and KKRRP motif, would play a critical role in positioning the
ligand into the corresponding binding sites of these two motifs. Assuming that initial
contact with the hMC2R occurs at the proposed KKRRP binding site, and this binding
event would then lead to the docking of the HFRW domain into its corresponding binding
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site of the receptor, altering the secondary structure of the GKPVG region of hACTH(124) would cause the HFRW motif unable to be properly positioned into the HFRW
binding site on the receptor (Figure 10). Based on these assumptions, this model would
explain the inability of α-MSH to activate MC2R, or even to act as a competitive
inhibitor of ACTH(1-24) (Buckley et al., 1981). It would appear that since α-MSH lacks
the KKRRP motif, this ligand cannot be properly oriented for inserting into the HFRW
binding site in melanocortin-2 receptor. On the other hand, α-MSH can successfully
activate MC1R, MC3R, MC4R, and MC5R, even without a complete KKRRP sequence
(Cone, 2006). In this regard, it would be reasonable to propose that these MCRs may
have a flexible binding site for HFRW motif, which allow both α-MSH and ACTH(1-24)
to activate MC1R, MC3R, MC4R, and MC5R.
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A.

B.

C.

D.

Figure 6. Activation curves of hMC2R by the stimulation of hACTH(1-24) analogs: A)
Zone A analogs; B) Zone B alanine substitution analogs; C). Zone B truncated analogs;
D) Zone C analogs
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A.

B.

Figure 7. Activation curves of hMC2R by the stimulation of hACTH(1-24) Zone D
analogs.
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A.

B.

Figure 8. A) hMC2R ligand binding analysis. B) Activation curves of hMC4R by the
stimulation of hACTH(1-24) Zone A analogs.
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Table 3. Effects of ACTH(1-24) analogs on hMC2R activation and 125I-ACTH binding
EC50 ± SEM (pM)

P Values Ki ± SEM (nM) P Values

ACTH(1-24)

4.2 ± 1.3

11.8 ± 8.4

A4

NA

148.2 ± 79.8

0.08

AFRW

36 ± 11

0.057

HARW

33505 ± 2559***

0.0001

HFAW

1845 ± 467**

0.008

HFRA

NA

A10-14

3608 ± 381***

0.0004

396.6 ± 126.7

0.2

AKPVA

6.1 ± 1.7

0.2

GAAVG

3.1 ± 1.4

0.7

GKAVG

3.7 ± 1.1

0.6

ACTH(1-22)

NA

ACTH(1-21)

NA

A5

12214 ± 4745*

0.03

459.7 ± 466.1*

0.02

AARRP

14.4 ± 3.3*

0.02

KKAAA

120 ± 24.5**

0.004

ACTH Analogs

Zone A

Zone B

Zone C

EC50 values are expressed as mean ± SEM (n=3). Statistical differences were assessed by
student t-test compared with ACTH(1-24) (*:P<0.05, **:P<0.005, ***: P<0.005). NA,
No activation
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Table 4. Effects of ACTH(1-24) Zone A analogs on hMC4R activation
ACTH Analogs

EC50 ± SEM (nM)

P Values

ACTH(1-24)

0.2 ± 0.85

A4

NA

AFRW

36 ± 8.9*

0.008

HARW

3128 ± 424**

0.0009

HFAW

5284 ± 580***

0.0004

HFRA

NA

EC50 values are expressed as mean ± SEM (n=3). Statistical differences were assessed by
student t-test compared with ACTH(1-24) (*:P<0.05, **:P<0.005, ***: P<0.005). NA,
No activation
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hMC2R
hMC4R
hMC1R
hMC3R
hMC5R

N-terminal
[---------TM1-------MK---------------------------HIINSYENINNTARNNSDCPRVVLPEEIFFTISIVGVLENLIVL
MVNS----THRGMHTSLHLWNRS---SYRLHSNASESLGKGYSDGGCYEQLFVSPEVFVTLGVISLLENILVI
M------AVQGSQRRLLGSLNST-------PTAIPQLGLAANQTGARCLEVSISDGLFLSLGLVSLVENALVV
MNAS-----CCLPSVQPTLPNGS--------EHLQAPFFSNQSSSAFCEQVFIKPEVFLSLGIVSLLENILVI
MNSS------FHLHFLDLNLNAT------EGNLS---GPNVKNKSSPCEDMGIAVEVFLTLGVISLLENILVI

hMC2R
hMC4R
hMC1R
hMC3R
hMC5R

--]
IC1
[---------TM2----------]
EC1
[----------TM3-------LAVFKNKNLQAPMYFFICSLAISDMLGSLYKILENIL-IILRNMGYLKPRGSFETTADDIIDSLFVLSLLGSI
VAIAKNKNLHSPMYFFICSLAVADMLVSVSNGSETIV-ITLLNSTD-TDAQSFTVNIDNVIDSVICSSLLASI
ATIAKNRNLHSPMYCFICCLALSDLLVSGSNVLETAV-ILLLEAGALVARAAVLQQLDNVIDVITCSSMLSSL
LAVVRNGNLHSPMYFFLCSLAVADMLVSVSNALETIM-IAIVHSDYLTFEDQFIQHMDNIFDSMICISLVASI
GAIVKNKNLHSPMYFFVCSLAVADMLVSMSSAWETIT-IYLLNNKHLVIADAFVRHIDNVFDSMICISVVASM

hMC2R
hMC4R
hMC1R
hMC3R
hMC5R

----]
IC2
[--------TM4---------]
EC2
[-------TM5---FSLSVIAADRYITIFHALRYHSIVTMRRTVVVLTVIWTFCTGTGITMVIFSHHVPTVITFTSLFPLMLVFILC
CSLLSIAVDRYFTIFYALQYHNIMTVKRVGIIISCIWAACTVSGILFIIYSDSSAVIICLITMFFTMLALMAS
CFLGAIAVDRYISIFYALRYHSIVTLPRARRAVAAIWVASVVFSTLFIAYYDHVAVLLCLVVFFLAMLVLMAV
CNLLAIAVDRYVTIFYALRYHSIMTVRKALTLIVAIWVCCGVCGVVFIVYSESKMVIVCLITMFFAMMLLMGT
CSLLAIAVDRYVTIFYALRYHHIMTARRSGAIIAGIWAFCTGCGIVFILYSESTYVILCLISMFFAMLFLLVS

hMC2R
hMC4R
hMC1R
hMC3R
hMC5R

------]
IC3
[-----------TM6-----------]
EC3
LYVHMFLLARSHTRKISTLP-------------RANMKGAITLTILLGVFIFCWAPFVLHVLLMTFCPSNPYCA
LYVHMFLMARLHIKRIAVLPG------TGAIRQGANMKGAITLTILIGVFVVCWAPFFLHLIFYISCPQNPYCV
LYVHMLARACQHAQGIARLHK-----RQRPVHQGFGLKGAVTLTILLGIFFLCWGPFFLHLTLIVLCPEHPTCG
LYVHMFLFARLHVKRIAALP----PADGVAPQQHSCMKGAVTITILLGVFIFCWAPFFLHLVLIITCPTNPYCI
LYIHMFLLARTHVKRIAALPGASS------ARQRTSMQGAVTVTMLLGVFTVCWAPFFLHLTLMLSCPQNLYCS

hMC2R
hMC4R
hMC1R
hMC3R
hMC5R

[-----------TM7-------]
C-terminal
CYMSLFQVNGMLIMCNAVIDPFIYAFRSPELRDAFKKMIFCSRYW
CFMSHFNLYLILIMCNSIIDPLIYALRSQELRKTFKEI-ICCYPLGGLCDLSSRY
CIFKNFNLFLALIICNAIIDPLIYAFHSQELRRTLKEVLTCSW
CYTAHFNTYLVLIMCNSVIDPLIYAFRSLELRNTFREILCGCNGMNLG
RFMSHFNMYLILIMCNSVMDPLIYAFRSQEMRKTFKEI-ICCRGFRIACSFPRRD

*

*

*

*

*

*

*

*

*

*

*

Figure 9. Human MCRs sequence alignment. Shaded residues indicate sites in which at
least 60% of the amino acids at that position are identical for all sequence. *: Positions
involved in the binding of HFRW motif in MC4R (Pogozheva et al., 2005).
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A.

B.

C.

Figure 10. Schematic diagram for the model of hMC2R activation. A) ACTH(1-24) can
bind to and activate hMC2R. B) ACTH(1-22) can bind to hMC2R but not activate it.
C). α-MSH cannot bind to hMC2R.
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CHAPTER TWO
Identification of an ACTH Antagonist

The primary role of ACTH is to stimulate the synthesis of glucocorticoids in
adrenal cortex via melanocortin-2 receptor (Chan et al., 2011). Due to the presence of
HFRW motif, which is the core sequence of melanocortin peptides (Schwyer, 1977),
ACTH is capable of activating any other receptor in this gene family. As concluded in
Chapter One, one of the distinct features of MC2R the need for both the HFRW and
KKRRP motif in order to activate the receptor. By contrast, α-MSH [Acetyl-ACTH(113)-amide] has the HFRW motif, but lacks the KKRRP motif, and as a result this ligand
cannot activate MC2R. Collectively these data point to the region at position 14 to 24 of
ACTH as a possible motif that could function as a competitive inhibitor of ACTH for
MC2R. In this chapter, ligand competition and binding assays will be utilized to examine
the potential of several truncated C-terminal analogs as ACTH antagonist that could
selectively target hMC2R.
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Results
hMC2R cAMP Response Analysis
To evaluate the direct response of activated receptor in transfected CHO cells,
cAMP measurement was used in the experiments of this chapter. To begin with, we
examined the cAMP response after 15-minute stimulation of ACTH(1-24), A5 analog,
and KKRRP analog. In the presence of IBMX, these analogs were introduced to the cells
individually, and then the cell lysate was harvested and assayed immediately using the
direct cAMP enzyme immunoassay kit. As indicated in Figure 11A, the cAMP
production in response to 100nM A5 analog was 200pmol, which was only 42% of the
amount of cAMP produced by ACTH(1-24) stimuli (P<0.5). The cAMP level was
undetectable when the cells were stimulated with 1nM A5 analog. Meanwhile, due to the
lack of HFRW motif, analog KKRRP was unable to induce a cAMP response at
concentration of 1nM or 100nM.
To examine whether HFRW and KKRRP motif that are present in separate
peptide fragments are sufficient to activate hMC2R, the transfected CHO cells were
incubated with 100nM KKRRP and 1µM α-MSH or 100nM KKRRP and 1µM ACTH(410). There was no receptor activation detected based on the level of cAMP production
(Figure 11B).

Ligand Competition cAMP Assay
As discussed in Chapter One, the KKRRP motif is the secondary binding site of
ACTH(1-24) for hMC2R. Consequently, ACTH(1-24) analogs containing KKRRP motif
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but lacking HFRW motif should be able to function as a competitive inhibitor of this
receptor. A serial of C-terminus analogs (Sequences shown in Table 2) were synthesized
and tested at a concentration of 1µM with the co-incubation of ACTH(1-24) ranging from
10-11 to 10-7M. We first examined analog KPV, KKRRP and RRP (ACTH position 11-24,
15-24, and 17-24). The co-incubation of these analog with ACTH(1-24) led to the
reduction of cAMP production at various degrees (Figure 12A). Analog KPV and RRP
decreased the maximal cAMP response by 30% and 20% respectively, whereas analog
KKRRP completely abolished the ACTH(1-24) induced cAMP response. Additionally,
the KKRRP analog fully kept this inhibitory effect when the analog concentration applied
to the cells was reduced from 1µM down to 100nM; at the concentration of 10nM,
KKRRP could still block 35% of ACTH(1-24) induced cAMP response (Figure 12C).
Thereafter, the inhibitory effect of two modified forms of KKRRP analogs was evaluated
as shown in Figure 12B. Attachment of an acetyl group at the N-terminus of KKRRP
analog (Ac-KKRRP) was not as an efficient antagonist as compared to KKRRP analog,
but it retained 30% inhibition ability, while alanine substitution at position 20-24
(KKRRPAs) caused this analog to lose the ability to compete with ACTH(1-24) (Figure
12B).

Ligand Binding Affinity Analysis
To determine the binding affinity of these truncated analogs, radioligand binding
assay was performed using 125I labeled ACTH(1-39) (Figure 12D). Compared with
ACTH(1-24) (Ki= 1.2×10-8M ± 8.4×10-9M), a right shift in ACTH(1-39) binding curve
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displayed with the co-incubation of analog RRP (Ki= 3.0×10-7M ± 8.8×10-8M) and
KKRRPAs (Ki= 8.7×10-8M ± 3.2×10-8M), indicating their low binding affinity. In
agreement with cAMP response analysis, analog KKRRP can bind to hMC2R most
efficiently (Ki= 2.5×10-8M ± 1.5 ×10-8M) among these analogs.

Discussion

The overproduction of ACTH(1-39) by the anterior pituitary gland, as a result of
Cushing’s Syndrome or due to chronic stress, leads to the over stimulation of MC2R on
adrenal cortical cells and the subsequent overproduction of cortisol (Cushing, 1932;
Arnaldi et al., 2003). In addition to the surgical resection of the underlying tumor,
medications currently used in the therapies of Cushing’s syndrome primarily target
adrenocortical steroidogenesis (e.g., ketoconazole and metyrapone), ACTH secretion
(e.g., bromocriptine and octreotide) or glucocorticoid receptor (e.g., mifepristone) (Tritos
and Biller, 2012). Nevertheless, due to the lack of selectivity, administration of these
medicines may induce many side-effects such as gastrointestinal toxicity, nausea, and
hypertension (Tritos and Biller, 2012). In the development of effective medication for
Cushing’s Syndrome, one strategy to prevent systemic effects and enhance the selectivity
to HPA axis would be to block the activation of MC2R by introducing an ACTH
antagonist.
Previous studies reported that truncated analog ACTH(6-24) could bind to
hMC2R that was expressed on OS3 adrenal cells, but completely lost the ability to
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activate the receptor (Chen et al., 2007); ACTH(11-24) can act as a competitive inhibitor
of ACTH(1-24) (Seelig et al., 1975). These observations shed a light to the identification
of a ACTH antagonist that embedded within the sequence of ACTH(1-24). As discussed
in Chapter One, HFRW motif is required in ACTH(1-24) to activate all melanocortin
receptors; therefore, the absence of this domain is necessary in the sequence of ACTH
antagonist. Moreover, α-MSH (acetyl-ACTH(1-13) amide) is sufficient to activate MC1R,
MC3R, MC4R and MC5R, but not to MC2R. In order to properly bind to MC2R,
KKRRP motif (position 15-19) is required to be present in the ligand. Clearly, position
14-24 of ACTH(1-24) is a critical region to study that would lead to the selectivity of
antagonist to MC2R. As a result, we evaluated the ability of competitive inhibition of
several truncated ACTH analog in CHO cells expressing hMC2R and mMRAP1.
Surprisingly, ACTH(15-24)/KKRRP was working as the best competitive inhibitor
compared with ACTH(11-24)/KPV and ACTH(17-24)/RRP, at the concentration as low
as 10-8M (Figure 12A, 12C). This finding was further supported by ligand binding
affinity analysis (Figure 11A). Although alanine substitution at position 20-23 in
ACTH(1-24) didn’t affect the activation of hMC2R (Chapter One), same replacement
performed in analog ACTH(15-24) did diminish the competition and binding ability of
this analog (Figure 12B; 11), suggesting the last five position may play a role in the
secondary structure of analog KKRRP that facilitates its binding to the receptor.
Collectively, these observations suggested that ACTH(15-24) can act as an antagonist of
ACTH(1-24) in our in vitro system.
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Over the past decade, many pharmaceutical and biotech companies have drawn
their attention to peptide drugs due to the distinctive advantages of this class of
medications, such as high bioactivity and specificity, minimal drug-drug interactions, as
well as low tissue accumulation and toxicity (Ayoub and Scheidegger, 2006). On the
other hand, stability of peptides is their major disadvantages that limited the success of
peptide drugs. The intrinsic properties of peptides could result in short half-life and low
bioavailability issues when administered in vivo (Ayoub and Scheidegger, 2006).
ACTH(15-24) is a short peptide with only ten amino acid residues. Hence, the main
challenge it may encounter in serum or plasma would be the peptidase degradation
predominantly by exopeptidases. To overcome this problem, the common approach is to
protect the free N- and C-terminus with minor modifications. For example, one of the
naturally modified hormones is α-MSH; under the protection of both amino-acetylation
and carboxy-amidation, it can only be degraded by endopeptidases in vivo (Marks et al.,
1976). In the case of somatostatin analogs, N-terminal acetylation alone was able to
expand the half-life from 3 minutes up to 400 minutes (Benuck and Marks, 1976). As a
result, we evaluated the competition ability of ACTH(15-25) when attached with an
acetyl group (analog Ac-KKRRP). Although this adjustment at N-terminus caused a
partial lose in its antagonist function (Figure 12B), whether this analog could make a
good drug candidate in in vivo system is waiting for further examinations.
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A.

B

Figure 11. cAMP response in transfected CHO cells after 15-minute stimulation of A).
ACTH(1-24), A5, or KKRRP; B).KKRRP/α-MSH or KKRRP/ACTH(4-10)
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A.

B.

C.

D.

Figure 12. ACTH(1-24) dose response curves with co-incubation of C-terminal truncated
analogs: A) 1µM of KPV, KKRRP and RRP; B) 1µM of KKRRP, Ac-KKRRP and
KKRRPAs; C) 1nM to 1µM KKRRP. D) Binding affinity of ACTH analogs at hsMC2R.
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CHAPTER THREE
Site-directed Mutagenesis of TM4, EC2, TM5 in Human MC2R

Extensive studies have been performed to examine the molecular basis
responsible for ligand binding and signaling in MC1R, MC3R, and MC4R (Yang et al.,
2000; Chen et al., 2006), and conserved residues in transmembrane domains of these
receptors have emerged as key elements that facilitate both α-MSH binding and receptor
activation (Haskell-Luevano et al, 1996). As reported by Pogozheva and colleagues, ten
residues in hMC4R that are involved in the binding of HFRW motif distributed in TM2,
TM3, TM6 and TM7 (Table 5 and Figure 13). Note that 90% of these residues are also
present at the same position in other melanocortin receptors of humans (MC1R, MC3R
and MC5R), and at least 70% of these residues are conserved in human, frog and rainbow
trout MC2R orthologs (Table 5). Since HFRW motif is required for the activation of all
melanocortin receptors (Schwyzer, 1977), it is reasonable to propose that MC2Rs use a
similar binding mechanism (TM2, TM3, TM6 and TM7) for the HFRW motif of
ACTH(1-24).
As shown in the sequence alignment in Figure 13, the differences in primary
sequence between human MC2R and MC4R are primarily in two aspects: 1). The amino
acid sequences of N-terminus, C-terminus, and IC3 in MC4R are significantly longer as
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compared with MC2R. 2). Primary sequence identity of TM1, EC1, TM4, EC2, and TM5
is less than 45% between MC4R and MC2R. These observations are consistent with
Pogozheva’s hypothesis that none of the proposed HFRW binding regions fall into these
domains. The low sequence identity of these domains may be the key to understand the
recognition mechanism which determines the ligand selectivity of MC2R—a secondary
binding site other than the HFRW motif to bind to, that allows this receptor to exclude αMSH while accepting ACTH(1-24).
Assuming that the 3-dimentional structure of MC2R orients the seven
transmembrane regions in a barrel conformation as shown in the schematic diagram in
Figure 14, then TM2, TM3, TM6, and TM7 would be in close proximity to interact with
HFRW motif, and EC2 could be positioned in the KKRRP binding site flanked by TM4
and TM5. After a careful comparison between the primary sequences of these domains in
difference species, we found that between the highly conserved intracellular loop2 and
the cytosolic region of TM5, there is a sharp dichotomy distinguishing MC2R primary
sequence from all other MCRs (Sequences alignment shown in Figure 15). Due to the
extremely low primary sequence identity of this continuous domain in MC2R orthologs,
EC2 with the flanking regions in TM4 and TM5 is likely the responsible domain for
creating a unique binding site for KKRRP motif in MC2Rs.
In this Chapter, 23 mutant hMC2R were synthesized for evaluating the
importance of this domain from G162 to P183 (See diagrams in Figure 5), in terms of
both receptor activation and plasma membrane expression levels. Since alanine is the
generally accepted amino acid of choice for mutagenesis substitution in this type of
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analysis (Yang et al., 2000), individual alanine substitution was used for replacing
original amino acid residues in mutagenesis in order to avoid disrupting receptor tertiary
structure. In the presence of mMRAP1, cAMP luciferase reporter assay was performed to
analyze the activation activity of these mutant hMC2Rs. All mutant receptors were tested
using hACTH(1-24) at concentrations ranging from 10-13M to 10-6M. A wild type
hMC2R was used as the positive control for each mutant receptor experiment. The basal
luciferase activity of each receptor was subtracted from the luminescence readings
individually. Then the dose response curves were plotted on a logarithmic graph using
the Michaelis-Menton equation (Kaleidograph software). EC50 values of ACTH(1-24)mediated response curves were used as the parameter to compare receptor activation
levels. Statistical difference of EC50 values between wild type hMC2R and mutants were
determined using unpaired Student t-test with equal variances. Significant difference was
confirmed when P<0.05. After ACTH signaling defect mutants were identified, cell
surface ELISA was performed on these receptors in the presence of mMRAP1 to evaluate
their trafficking efficiency.

Results

Effects of Single Alanine Substitution in hMC2R for ACTH Signaling
In this study, alanine substitution was individually introduced to positions of
interest in hMC2R, including six amino acid residues in TM4 (G162- I167), seven
residues in TM5 (T177-P183), and the entire EC2 (F168-I176). We expressed the mutant
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receptor in CHO cells in the presence of mMRAP1, and the functions of these mutants
were evaluated using cAMP responsive reporter assay. As summarized in Table 6, in 22
single mutant hMC2Rs we examined, 16 mutant receptors showed no changes in the
ACTH(1-24)-mediated response curves as compared with wild type hMC2R, suggesting
that alanine substitution at these positions did not affect hMC2R/ACTH interaction and
receptor activation. Meanwhile, we identified six mutant receptors that displayed
significant decreases in ACTH(1-24)-mediated responses (P<0.05). These positions are
T164, F168, S169, H170, F178 and L181 (Table 6).
Within six TM4 mutants we examined, only one position, T164, had a significant
negative effect on ACTH dose response curve (Figure 16). The EC50 of ACTH(1-24) for
mutant T164 was (7.5±1.59)×10-12 M as compared to a EC50 of (2.7±1.23)×10-12 M for
wild type hMC2R (P=0.038) (Table 6). Of 9 residues in the domain of EC2, alanine
substitution on three successive positions that are located at the very beginning of this
loop displayed significant reduction in ACTH(1-24) responses (Figure 17A). The EC50
values for these mutants, F168, S169 and H170, were (1.4±0.4)×10-11 M, (1.7±0.5)×10-11
M, and (6.1±2.0)×10-11 M, which were approximately 4-fold, 5-fold, and 16-fold of the
EC50 of the wild type hMC2R (P=0.03, 0.02, and 0.01, respectively) (Table 6). Clearly,
H170 was the most important site in EC2 that mediated receptor activation. In addition,
positions F178 and L181 identified from TM5 mutants had even greater effects than all
positions tested in TM4 and majority in EC2 (Figure 18). As indicated in Table 6, the
EC50 values for F178 and L181 were (6.6±1.0)×10-10 M and (3.7±1.4)×10-11 M, which
were approximately 174-fold and 10-fold of wild type hMC2R EC50. Hence, mutant F178
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in TM5 produced the greatest right-shift in ACTH(1-24) dose response curve (Figure
18A), and this position is likely one of the core residues that mediate the receptor/ligand
interaction of hMC2R.
Next, we put alanine substitutions on both significant phenylalanine positions
F168 and F178, and examined the activity function of this mutant (Figure 19A). Albeit
EC50 of mutant FF was (9.2±2.1)×10-8 M and ACTH dose response curve was greatly
shift to the right, this receptor kept full activation ability when stimulated with 10-6 M
ACTH, indicating that double substitution of F168 and F178 cannot completely block
ACTH signaling. Hence, there are other positions involved in this binding event. Finally,
we substituted all six significant positions (T164, F168, S169, H170, F168 and F178)
with alanine residues to make an hMC2R 6A mutant, and this mutant completely lost the
activation activity (Figure 19B)

Effects of Single Alanine Substitution in hMC2R for Receptor Trafficking
In order to eliminate the possibility of trafficking defects introduced by alanine
mutations, we co-transfected CHO cells with mMRAP1 and individual activation defect
mutant hMC2R identified by cAMP luciferase reporter assay, and performed cell surface
ELISA to evaluate the plasma membrane expression levels of these mutants. All
experiments were executed in triplicates. Data were first subtracted by the background
signals, converted to the ratio of plasma membrane expression to total expression, and
then normalized to wild type hMC2R. As indicated in Figure 20, albeit mutant S169 and
L181 showed a lower level of surface expression as compared with wild type hMC2R,
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Student t-test analysis showed that none of these activation defect mutants demonstrated
significant trafficking impairment.

Discussion

By virtue of the functionally important residues that were previously identified in
MC1, MC3, and MC4R, nine residues in MC2R were found to be responsible for ACTH
binding and signaling (Chen et al., 2007). Within these positions, seven residues are
located in TM2, TM3, TM6 and TM7, which is the proposed HFRW motif binding site
identified from MC4R (Pogozheva et al., 2005). Not surprisingly, the other two residues
in these positions, F168 in EC2 and F178 in TM5, are both unique amino acids in MC2R,
and their position fall out of the proposed binding pocket for HFRW motif (Chen et al.,
2007). As discussed in the ligand binding studies in Chapter One, the recognition sites for
HFRW and KKRRP motif on ACTH(1-24) must span two portions in the receptor. Based
on the 3-D structure of receptor (Figure 14), if the HFRW motif is positioned between
TM2, TM3, TM6 and TM7, then the logical location for the KKRRP motif to bind must
be present in TM4, EC2, and TM5. These observations supported our hypothesis that
TM4, EC2 and TM5 may indirectly interact with the KKRRP motif, which in turn
determine the ligand selectivity of MC2R.
In this Chapter, we systematically characterized the functional expression of 22
single-mutation hMC2Rs from position G162 to P183, which cover the entire EC2 and
the flanking regions in TM4 and TM5. As indicated in Table 6 and Figure 16-18, 6
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mutants, T164, F168, S169, H170, F178, and L181, caused significant decrease in ACTH
response curve while trafficking defects were undetectable in plasma membrane
expression analysis (Figure 20). In a previous study based on type 1 FDG mutant MC2R
cases, Chung and colleagues identified six trafficking-competent mutations with ACTH
signaling defects (D20N, 144M, D103N, D107N, R128C, and H170L) from 24 naturally
occurring missense mutations found in these patients (Figure 21A; Chung et al., 2008).
D107N and R128C are located in TM3, providing the evidence for the importance of this
transmembrane domain in the interaction between MC2R and ACTH. These findings also
supported Pogosheva’s hypothesis that the binding site for HFRW motif in MCRs is
between TM2, TM3, TM6 and TM7. Note that only one position (H170L) was detected
in the region we are focusing on (TM4/EC2/TM5). Other than residue H170, two
phenylalanine residues F168 and F178 were the previously reported by Chen’s group
(Chen et al., 2007). Our receptor activation results from double phenylalanine mutation
(FF) indicated that removing these residues at the same time cannot completely block
ACTH signaling (Figure 19A). Hence, there must be more residues involved in this
process, and it appears to be position T164, S169 and L181 as we identified from our
target region. In addition, these residues were the first time to be discovered that impaired
ACTH(1-24) signaling without disrupting human MC2R trafficking in the presence of
mMRAP1.
Taken together, the distribution of these essential residues is as follows: one
position in TM4, two discrete positions in TM5, and three successive positions located at
the beginning of EC2 (Summarized in Figure 21B). Notably, hMC2R has a relatively
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short extracellular loop 2, which is composed of only nine amino acids. Thus, 33%
residues of EC2 are involved in the binding of ACTH, suggesting a critical role of this
loop playing in the proposed KKRRP motif binding region. When these positions were
substituted by alanine residues at the time, the ACTH(1-24) was completely blocked. In
order to confirm this effect was solely induced by the inactivated binding sites but not
due to the trafficking defects of this mutant, the receptor cell surface expression analysis
needs to be done in the future.
As described in Chapter One, our model for the binding of ACTH to MC2R is
that the ligand first makes contact with the receptor at a KKRRP binding site and then
activation is possible when the HFRW motif of the ligand is inserted into the
corresponding binding site on the receptor. If the primary binding site for KKRRP motif
is disabled in MC2R, then ACTH(1-24) would be rejected by this receptor just as αMSH. Would this alternation completely prevent the binding of ACTH(1-24) to the
receptor? Would it eliminate the ACTH response of MC2R, or just take away its ligand
selectivity? In this regard, a mutant hMC2R with alanine substitutions at all six residues
identified in this Chapter will be examined in future studies.
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Table 5. Proposed HFRW binding sites in MC4R and corresponding residues of MC2R.

AA

MC4R

Region

MC2R

H

X

RT

H

X

RT

E100

TM2

+

+

+

+

+

+

D122

TM3

+

+

+

+

+

+

D126

TM3

+

+

+

+

+

+

I129

TM3

+

+

+

-

-

-

L133

TM3

+

+

+

+

+

-

W258

TM6

+

+

+

+

+

+

F261

TM6

+

+

+

+

+

+

H264

TM6

+

+

+

+

+

+

N285

TM7

+

+

+

-

+

-

L288

TM7

+

+

+

-

-

+

H: Human; X: Xenopus tropicalis; RT: Rainbow trout (Onchorynchus mykiss)
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hMC2R
hMC4R

hMC2R
hMC4R

hMC2R
hMC4R

N-terminal
[---------TM1----------]
MK--------------------HIINSYENINNTARNNSDCPRVVLPEEIFFTISIVGVLENLIVLLAVF
MVNSTHRGMHTSLHLWNRSSYRLHSNASESLGKGYSDGGCYEQLFVSPEVFVTLGVISLLENILVIVAIA
IC1
[---------TM2---------]
EC1
[----------TM3---------KNKNLQAPMYFFICSLAISDMLGSLYKILENILIILRNMGYLKPRGSFETTADDIIDSLFVLSLLGSIFS
KNKNLHSPMYFFICSLAVADMLVSVSNGSETIVITLLNSTD-TDAQSFTVNIDNVIDSVICSSLLASICS
*
*
* *
*
--]
IC2
[--------TM4---------]
EC2
[-------TM5--LSVIAADRYITIFHALRYHSIVTMRRTVVVLTVIWTFCTGTGITMVIFSHHVPTVITFTSLFPLMLVFIL
LLSIAVDRYFTIFYALQYHNIMTVKRVGIIISCIWAACTVSGILFIIYSDSSAVIICLITMFFTMLALMA

hMC2R
hMC4R

------]
IC3
[-----------TM6-----------]
EC3
CLYVHMFLLARSHTRKISTLP-------RANMKGAITLTILLGVFIFCWAPFVLHVLLMTFCPSNPYCAC
SLYVHMFLMARLHIKRIAVLPGTGAIRQGANMKGAITLTILIGVFVVCWAPFFLHLIFYISCPQNPYCVC
* * *

hMC2R
hMC4R

[----------TM7--------]
C-terminal
YMSLFQVNGMLIMCNAVIDPFIYAFRSPELRDAFKKMIFCSRYW
FMSHFNLYLILIMCNSIIDPLIYALRSQELRKTFKEI-ICCYPLGGLCDLSSRY
* *

Figure 13. Sequence alignment of human MC2R and MC4R. Positions shaded indicate
identical amino acids in these receptors. * indicates proposed amino acids that are
involved in HFRW binding sites in MC4R as reported by Pogozheva.
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Figure 14. Schematic diagram of MC2R proposed binding sites for HFRW motif and
KKRRP motif.

56

hMC2R
xMC2R
rMC2R
zMC2R

[----Mutant region---]
IC2
TM4
EC2
TM5
5
IAADRYITIFHALRYHSIVTMRRTVVVLTVIWTFCTGTGITMVIFSHHVPTVITFTSLFPLMLVFILCLYVHMF
IAADRYITVFHALHYHNIMTVKRASVILAVIWTFCGGSGIAIIMLFHDTAMIICLTVMFLLLLVLIVCLYIHMF
IAVDRYVTIFHALRYHNIMTTRRAAAALAGIWALCGVAGAVMVAFCDATVIKIFFIVLFLISLLLILFLYVHMF
IAVDRYISIFHALRYHMLMTMRRVLIILFTIWVLCGTSGALMVGFFEAATVTIFFIVLFFTALLLILLLYVHMF

hMC1R IAVDRYISIFYALRYHSIVTLPRARRAVAAIWVASVVFSTLFIAYYDHVAVLLCLVVFFLAMLVLMAVLYVHML
xMC1R IAIDRYITIFYALRYHSIMTLRRVVIAIGVIWSVSLVCAAIFIVYHESRAVILCLIVFFLFMLALMVALYIHMF
zMC1R IAADRYITIFYALRYHSIMTTQRAVGIILVVWLASITSSSLFIVYHTDNAVIACLVTFFGVTLVFTAVLYLHMF
hMC3R IAVDRYVTIFYALRYHSIMTVRKALTLIVAIWVCCGVCGVVFIVYSESKMVIVCLITMFFAMMLLMGTLYVHMF
xMC3R IAIDRYITIFYALRYHSIMTVKKAIALIVVIWTSCIICGIVFIVFSESKTVIVCLITMFFTMLVLMATMYVHMF
zMC3R IAVDRYVTIFYALRYHSIVTVRRALVAIAVIWLVCVVCGIVFIVYSESKTVIVCLITMFFAMLVLMATLYVHMF
hMC4R IAVDRYFTIFYALQYHNIMTVKRVGIIISCIWAACTVSGILFIIYSDSSAVIICLITMFFTMLALMASLYVHMF
xMC4R IAVDRYFTIFYALQYHNIITVRRAVVIISCIWTACSISGVLFIIYYDSAVVIICLISIIFTMLALMASLYVHMF
zMC4R IAVDRYITIFYALRYHNIMTQRRAGTIITCIWTFCTVSGVLFIVYSESTTVLICLISMFFTMLALMASLYVHMF
hMC5R IAVDRYVTIFYALRYHHIMTARRSGAIIAGIWAFCTGCGIVFILYSESTYVILCLISMFFAMLFLLVSLYIHMF
xMC5R IAVDRYVTIFYALRYHNIMTMRRAGIIIACIWTFCTGCGIIFILYYESTYVIICLITMFFTMLFLMVSLYIHMF
zMC5R IAVDRYVTIFYALRYHNIMTVRRAALIIGGIWTFCTGCGIVFIIYSDNTSVIVCLVSMFFIMLALMASLYSHMF

Figure 15. MCRs sequence alignment from IC2 to TM5. Positions shaded in black
indicate sites in which 75% of the amino acids at that position are identical for all
sequence; positions shaded in white indicate sited in which at least 75% of the amino
acids are identical in MC1R, MC3R, MC4R and MC5R. h: human; x: Xenopus tropicalis;
r: rainbow trout (Oncorhynchus mykiss); z: zebra fish (Danio rerio).

57

A.

B.

Figure 16. ACTH(1-24) dose response curves of TM4 mutant hMC2Rs in the presence
of mMRAP1.
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A.

B.

C.

Figure 17. ACTH(1-24) dose response curves of EC2 mutant hMC2Rs in the presence of
mMRAP1.
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A.

B.

C.

Figure 18. A-C) ACTH(1-24) dose response curves of TM5 mutant hMC2Rs in the
presence of mMRAP1.
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A.

B.

Figure 19. A) ACTH(1-24) dose response curves of hMC2R FF mutant (F168 & F178).
B) ACTH(1-24) dose response curves of hMC2R 6A mutant
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Table 6. EC50 values of mutant hMC2R.
Domain

Alanine Substitution

EC50 ± SEM (10-12M)

P Values

WT

N/A

3.8 ± 0.3

N/A

TM4

G162
I163
T164
M165
V166
I167

4.5 ± 1.79
4.3 ± 1.15
7.5 ± 1.59*
4.6 ± 0.98
7.2 ± 1.6
3.4 ± 0.8

0.23
0.20
0.038
0.42
0.10
0.60

EC2

F168
S169
H170
H171
V172
P173
T174
V175
I176

14.1 ± 4.6*
17.2 ± 5.1*
60.9 ± 20.3*
5.0 ± 0.61
3.3 ± 3.87
4.8 ± 1.02
5.9 ± 1.7
4.4 ± 2.4
1.7 ± 0.8

0.03
0.02
0.01
0.08
0.40
0.13
0.10
0.4
0.2

TM5

T177
F178
T179
S180
L181
F182
P183

5.4 ± 1.60
660 ± 100**
10 ± 2.7
8.1 ± 7.4
37 ± 14*
4.2 ± 1.5
9.1 ± 3.3

0.44
0.0014
0.099
0.33
0.041
0.51
0.13

Double
Mutation

F168 & F178
(FF)

92000 ± 21000*

0.006

Sextuple
Mutation

T164, F168, S169,
H170, F168, F178
(6A)

N/A

EC50 values are expressed as mean ± SEM (n=3). Statistical differences were assessed
by student t-test compared with ACTH(1-24) (*:P<0.05, **:P<0.005). N/A: No
activation.
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Figure 20. Cell surface expression analysis of ACTH signaling defect mutants.
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A.

B.

Figure 21. Schematic plot of the MC2R mapping the locations of A) 6 traffickingcompetent mutations identified from Type 1 FDG (Chung et al., 2008). B) 6 residues
identified in this study for the proposed KKRRP motif binding site.
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CHAPTER FOUR
Ligand Selectivity Properties of Rainbow Trout Melanocortin-2 Receptor

According to the 2R hypothesis, the first gene duplication of ancestral MCR gene
yielded two paralogous genes (MCa and MCb receptors) in agnathan vertebrates, and then
the second duplication event produced four paralogous genes (MC1R, MC5/2R, MC3R
and MC4R) in ancestral gnathostomes (Vastermark and Schioth, 2011). As to the fifth
paralogous gene MC2R, which could be activated only by ACTH, appeared in the
ancestral bony fishes and has since radiated throughout the extant bony vertebrate classes
(Schioth et al., 2005). Recent studies revealed that a MC2R ortholog cloned from
cartilaginous fish Elephant shark could be transported to plasma membrane in the
absence of MRAP1, and it is the only MC2R currently identified that can be activated by
ACTH and MSHs (Reinick et al., 2012). These observations indicated that MC2R
dependence on MRAP1 for functional activation and the exclusive selectivity of this
melanocortin receptor for ACTH are features that emerged after the divergence of the
ancestral cartilaginous fishes and the ancestral bony fishes more than 400 million years
ago. Therefore, understanding the ligand selectivity features of a bony fish MC2R would
be an essential component in modeling the evolution MC2R activation. In this study,
rainbow trout (Oncorhynchus mykiss) MC2R (rtMC2R) was selected for demonstrating
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teleost MC2R activation. Like the mammalian MC2Rs, rtMC2R requires the presence of
MRAP1 to function properly (Liang et al., 2011). In the co-evolution of MC2R and
MRAP1 during the radiation of vertebrates, it appears that at least a tetrapod branch and a
bony fish branch have emerged with respect to the interaction between MC2R and
MRAP1 (Liang et al., 2011). Since we started this project when the genes encoding
rainbow trout MRAPs had not been identified yet, zebra fish MRAP1 (zfMRAP1) was
co-expressed with rtMC2R within CHO cells in order to obtain the optimal ACTH
responses.
In the analysis of hACTH(1-24) and hMC2R interactions (Chapter One), amino
acid residues within Zone A, Zone B, and Zone C were involved in ACTH binding and
signaling to varying degrees. To evaluate the functions of these domains in the activation
activities of rtMC2R, we did a comparative study using the same analogs as Chapter One
(See sequences in Table 2): (1) Zone A analogs—H6F7R8W9; (2) Zone B analogs—
G10K11P12V13G14; and (3) Zone C analogs—R15K16R17R18P19. Note that the position 15 of
rtACTH(1-24) as well as many other vertebrate species is an arginine (R15), instead of a
lysine (K15) in hACTH(1-24) (Figure 22), hence it is referred as R/KKRRP motif for this
Chapter. Both of these basic amino acids are generally considered to be interchangeable
and able to readily substitute for one another. In addition, it has been reported that
hACTH(1-24) can fully stimulate rtMC2R that are expressed in CHO cells in the
presence of zfMRAP1 (Liang et al., 2011). Hence, hACTH(1-24) was used in this study
as the wild-type rtACTH(1-24).
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Results

Ligand Selectivity of rtMC2R
Zone A analogs
Five Zone A analogs (See sequences in table 2) were applied individually to CHO
cells transiently transfected with rtMC2R and zfMRAP1, and CRE-Luc activity was
measured after 4 hours of stimulation (Figure 23A). Consistent with the parallel
experiment on hMC2R, replacing the entire HFRW motif abolished rtMC2R response
completely. Nevertheless, the importance of the four positions in Zone A with respect to
the activation of rtMC2R was different as compared to hMC2R. Firstly, all four analogs
(AFRW, HARW, HRAW, and HFRA) greatly diminished rtMC2R activation with a 23fold, 49-fold, 1400-fold, and 681-fold increase in EC50 values (Table 7), whereas for
hMC2R, ARFW analog did not significantly alter the dose response curve. Secondly,
analog HFRA was able to stimulate weak rtMC2R activation at the concentrations higher
than 10-7M, whereas the same analog failed to activate hMC2R. Finally, the order of
effectiveness of these positions affecting rtMC2R activation is R8>W9>F7>H6.

Zone C analogs
To determine the role of R/KKRRP motif on the activation of rtMC2R, CHO cells
expressing rtMC2R and zfMRAP1 were challenged with three Zone C analogs
respectively (See sequences in Table 2). In the absence of R/KKRRP motif, analog A5
failed to promote any stimulatory effect on rtMC2R even at concentration of 10-6M
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(Figure 23B), clearly indicating that this motif is equally critical as HFRW motif.
Additionally, position R15K16 and R17R18P19 were tested separately using analog AARRP
and KKAAA. The EC50 values of KKAAA and AARRP were significantly increased up
to 1112-fold and 615-fold as compared with hACTH(1-24) (Table 7).

Zone B analogs
The importance of the region between HFRW and KKRRP was first examined
using four ACTH(1-24) analogs with alanine substitutions at G10K11P12V13G14, G10G14,
K11P12, and P12 (Analog A10-14, AKPVA, GAAVG, and GKAVG in Table 2). Generally,
alanine substitution at Zone B had greater effects on rtMC2R activation curves than
hMC2R. As indicated in Figure 23C and Table 7, both A10-14 and AKPVK significantly
reduced activation activity by 376-fold and 67-fold increase on EC50 values, while analog
GAAVG, and GKAVG also introduced a right shift in activation curve, albeit the EC50
values were not statistically larger than hACTH(1-24).Two truncated Zone C analogs,
ACTH(1-21) and ACTH(1-22), were also tested on rtMC2R. Note that skipping position
G10G14 or K11P12V13 in Zone B induced a complete loss in hMC2R activation (Figure 6C).
Similar scenario was observed in rtMC2R activation curves. Receptor activation in
response to both ACTH(1-21) and ACTH(1-22) were undetectable when analog
concentration was lower than 10-7M (Figure 23D).
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Discussion

As the core sequence of hACTH(1-24), HFRW motif plays an essential role in
activating hMC2R, with the tryptophan at the last position that predominantly contributes
to the function of this motif (Figure 6A). In the case of rtMC2R, A4 analog did not have
any stimulatory effect even at concentration of 10-6M (Figure 23A), hence, HFRW motif
is also required for the activation of rtMC2R. Nevertheless, the importance of each
position within this region results in a slightly different scenario. Replacement of a single
alanine at any of these positions significantly diminished the receptor activation activity,
whereas none of them was able to completely abolish the stimulatory effect at higher
doses (Figure 23A). It appears that histadine6 and phenylalanine7 that establish the
reverse β-turn structure in α MSH (Ying et al., 2003) are actually less important than
tryptophan9 and arginine8 in the interaction of hACTH(1-24) and rtMC2R (Table 7).
These observations are mostly consistent with hMC2R indicating that the side chains of
tryptophan9 and arginine8 may play an essential role interacting with rtMC2R.
Next, we examined the effect of alanine substitutions at R/KKRRP motif on
rtMC2R activation. As discussed in Chapter One, hMC2R recognizes the R/KKRRP
motif in hACTH(1-24) as a significant binding site that determines its ligand selectivity
property. Not surprisingly, alanine substitutions at entire KKRRP motif caused analog A5
fully lost the ability to stimulate rtMC2R (Figure 23B). Note that replacing the entire
R/KKRRP motif with alanine is not sufficient to eliminate the stimulatory effect in
human MC2R at concentration of 10-6M, whereas in rtMC2R ligand activation study, the
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absence of receptor activity acquired from A5 analog dose response curve has been
clearly supporting the secondary binding site hypothesis. Additionally, it appears that
R15K16 motif and R17R18P19 motif are equally contributing to this binding site (Figure 23A
and Table 7).
Having confirmed the same activation sites HFRW motif and R/KKRRP motif for
rtMC2R, we evaluated whether the G10K11P12V13G14 sequence between these two motifs
is as critical as it is in hMC2R. As compared to hMC2R, alanine substitutions at entire
Zone B had less negative effects on rtMC2R activation curve, whereas individual
substitution caused a greater right-shift in each curve (Figure 23C and Table 7). With
regard to Zone B truncated analogs, albeit a weak activation activity appeared at
concentration higher than 10-7M, both ACTH(1-22) and ACTH(1-21) greatly diminished
rtMC2R responses (Figure 23D). Collectively, the relative distance between HFRW motif
and R/KKRRP motif plays a more important role than the sequence of this region.
According to the proposed model for the interaction between ACTH(1-24) and
MC2R (Figure 10), R/KKRRP motif first binds to MC2R, and HFRW motif is then
positioned in its corresponding binding site, leading to the activation of receptor. In
agreement of this hypothesis, our results obtained from rtMC2R indicated that R/KKRRP
motif, HFRW motif, as well as the amino acid sequence in between are absolutely
required for the activation of the activation of rtMC2R (Figure 23). As compared to the
influence of these analogs on hMC2R activation, individual residues within these motifs
may play a slightly different role in terms of the interaction with certain residues of the
receptor, whereas the importance of three motifs was consistent in these receptors. A
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comparative analysis between human and rainbow trout MC2R will be discussed in next
chapter.
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Human
Chicken
Gecko
Xenopus
Trout
Dogfish

[------ACTH(1-39)---------------------]
[------ACTH(1-24)------]
[A ][ B ][ C ]
SYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEP
SYSMEHFRWGKPVGRKRRPIKVYPNGVDEESAESYPMEF
SYAMEHFRWGKPVGRKRRPVRVYPNGVEEESSESYPQEF
AYSMEHFRWGKPVGRKRRPIKVYPNGVEEESAENYPMEL
SYSMEHFRWGKPVGRKRRPVKVYTNGVEEESSEAFPSEM
SYSMEHFRWGKPMGRKRRPIKVYPNSFEDESVENMGPEL

Figure 22. Amino acid sequence alignment of ACTH in different species. Residues
shaded in grey are sites at least 83% identical in all sequence.
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A.

B.

C.

D.

Figure 23. Activation curves of rtMC2R by the stimulation of hACTH(1-24) analogs: A)
Zone A analogs; B) Zone C alanine substitution analogs; C). Zone B alanine substitution
analogs; D) Zone B truncated analogs.
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Table 7. Effects of ACTH(1-24) analogs on rtMC2R activation.
-11

Analogs

EC50 ± SEM (10 M)

P value

Wild-type

hACTH(1-24)

3.3 ± 1.4

Zone A

A4

N/A

AFRW

77 ± 20*

0.01

HARW

163 ± 54.4*

0.02

HFAW

4614 ± 1869*

0.03

HFRA

2250 ± 1400*

0.03

A10-14

1242 ± 161**

0.0008

A10/14

222 ± 56*

0.01

KP

27.8 ± 12.3

0.06

P12

8.1 ± 2.0

0.06

ACTH(1-22)

N/A

ACTH(1-21)

N/A

A5

N/A

AARRP

2030 ± 489*

0.007

KKAAA

3668 ± 778**

0.0046

Zone B

Zone C

EC50 values are expressed as mean ± SEM (n=3). Statistical differences were assessed by
student t-test compared with ACTH(1-24) (*:P<0.05, **:P<0.005). NA, No activation
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CHAPTER FIVE
Site-directed Mutagenesis of TM4, EC2, TM5 in Rainbow Trout MC2R

When ancestral teleosts diverged from ancestral cartilaginous fishes over 400
million years ago, their melanocortin-2 receptor acquired two distinct features that were
retained in MC2Rs in amphibians (Liang et al., 2011) and mammals (Cone, 2006):
MRAP1 dependence and melanocortin ligand selectivity (Reinick et al., 2012). While
these common features are shared by teleosts and tetrapods, during the co-evolution of
MC2R, MRAP1 and ACTH, subtle variations could have arose. Take as an example a
comparison of the MC2R circuit in humans and the rainbow trout. First examining the
ligands, 92% of amino acid residues in the sequence of rainbow trout ACTH(1-24) are
identical to human ACTH(1-24). However, the primary sequence identity of
melanocortin 2 receptor of these two species drops to 47% (Figure 24).
Analogs of ACTH(1-24) in the three zones had adverse effects on the activation
of both human and rainbow trout receptors, and there were subtle differences in the ways
that zone A, B and C analogs interacted with these receptors. From the mutant hMC2R
experiment discussed in Chapter Three, we have identified six significant sites within
TM4/EC2/TM5 region which was responsible for the proposed binding domain for
KKRRP motif. In order to find out whether rtMC2R use similar positions or residues as
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hMC2R for the interaction with ACTH(1-24), we designed mutant constructs of rtMC2R
with alanine substitutions within the same region as the hMC2R mutant study. Since
TM4/EC2/TM5 region (22 positions) of rtMC2R contains three neutral, non-polar alanine
residues (A156, A160 and A164), we eventually made 19 mutant rtMC2R for receptor
activation evaluation using cAMP luciferase reporter assay. For these experiments the
wild-type and single alanine mutant constructs of rtMC2R were co-expressed in CHO
cells with zfMRAP1 as described in Chapter Four. Luminesce data for receptor activation
levels were analyzed as described in Chapter Three.

Results

Effects of single alanine substitution in rtMC2R for ACTH signaling
As performed the comparative experiments for hMC2R mutants study, the
corresponding mutated regions of rtMC2R are V153-A160 in TM4, EC2 (F161-I169),
and F170-F175 in TM5. A total of 19 mutant rtMC2Rs were individually co-expressed
with zfMRAP1 in CHO cells, and receptor functions were examined by cAMP
responsive reporter assay. These mutant receptors included 5 mutants at TM4, 8 mutants
at EC2, and 6 mutants at TM5. As summarized in Table 8, of 19 residues we examined,
11 residues did not affect ACTH(1-24)-mediated response curve when replaced with
alanine. In other words, there were 8 mutant receptors (V157, M158, V159, F161, K168,
F171, I172, and F175) that displayed significant decrease in ACTH(1-24)-mediated
responses as compared with wild type rtMC2R (P<0.05), whereas in the same region
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examined in hMC2R, we only identified 6 significant positions (See Chapter Three,
Table 7).
EC50 value of ACTH(1-24) on wild type rtMC2R was (4.6±0.7)×10-11M, which
was the positive control for all mutant rtMC2Rs. Compared with wild type rtMC2R, three
successive positions in TM4 mutants, V157, M158, and V159, had significant negative
effects on ACTH dose response curve (Figure 25). The EC50 values of these mutants
were (1.9±0.6)×10-10M, (1.5±0.3)×10-10M, and (5.1±1.2)×10-9M, which were
approximately 4-fold, 3-fold, and 110-fold of the wild type hMC2R EC50 value (P=0.04,
0.03, and 0.01, respectively) (Table 8). Note that there was only one significant residue
identified from TM4 mutants of hMC2R. Albeit the amino acid residue was threonine
(T164) in human receptor instead of valine (V157) in rainbow trout MC2R, they are
located at the same position of TM4, indicating a critical role of this position in both
human and rainbow trout ACTH/MC2R interaction and receptor signaling.
From eight EC2 mutant receptors, we identified two residues that displayed
significant reduction in ACTH(1-24) responses (Figure 26): F161 with a EC50 of
(2.2±0.7)×10-10M (P=0.045) and K169 with a EC50 of (8.2±0.2)×10-11M (P=0.02) (Table
8). Mutation at these residues induced a 5-fold change in EC50 of F161and a 2-fold
increase in EC50 of K169. Compared with the three significant positions (F168, S169 and
H170) identified from hMC2R EC2 mutants, position F161 was conserved and also
important in rainbow trout and human receptor (F168), while position K169 was
significant for ACTH interaction with rtMC2R but not for hMC2R.
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Three out of six TM5 mutants greatly diminished ACTH(1-24) responses as
compared with wild type rtMC2R (Figure 27A-B), including F171(EC50 =(2.1±0.8)×109

M), I172 (EC50 =(2.6±0.8)×10-10M) and F175(EC50=(4.6±2.0)×10-9M) (Table 8). EC50

values of these mutants were approximately 47-fold, 6-fold, and 100-fold of wild type
rtMC2R EC50 respectively (P= 0.03, 0.03, 0.04). In addition, position F171 (which is
F178 in hMC2R) is a conserved residue in MC2Rs but different with all other MCRs.
Mutation on this position greatly altered ACTH(1-24) response in both hMC2R and
rtMC2R. These observations indicated that this position is involved in the ligand
selectivity of MC2Rs.
Further, we replaced seven significant residues (V157, M158, V159, F161, F171,
I172, and F175) with alanine residues in one mutant rtMC2R. The substitutions caused
this mutant receptor to lose ACTH(1-24) response completely (Figure 27C). In order to
rule out the possible defects on receptor trafficking that might be introduced by alanine
substitutions, cell surface ELISA will be performed on rtMC2R mutants in the future.

Discussion

As discussed in Chapter Three, within TM4/EC2/TM5 region (G162-P183) of
human MC2R, we identified six positions that were involved in ACTH(1-24) signaling
but not the trafficking of receptors, including T164, F168, S169, H170, F178, and L181.
The corresponding 22 amino acid residues in rainbow trout MC2R are from V153 to
F175, and we found 8 residues that significantly decreased ACTH(1-24) responses,
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which are V157, M158, V159, F161, K168, F171, I172, and F175. Since rtMC2R has a
shorter N-terminus than hMC2R, the same position we examined in these two receptors
was numbered differently. Therefore, we marked all 14 significant residues with the
degrees of EC50 fold change on TM4/EC2/TM5 sequence alignment diagram for a better
comparison (Figure 28). As compared with the EC50 of wild type MC2R, residues that
had significant larger EC50 were shaded in red in this diagram, suggesting that ACTH(124) response were substantially diminished in these mutants. The sequence alignment
clearly revealed that three significant sites that were involved in hMC2R/ACTH
interaction were important for rtMC2R signaling as well. These residues are T164, F168
and F178 in hMC2R, and V157, F161, and F171in rtMC2R. At the site T164/V157 of
TM4, albeit the threonine in hMC2R was replaced by a valine in rtMC2R, these two
amino acids are structurally very similar to each other. The other two positions are both
phenylalanine residues F168/F161 and F178/F171, which are located at the beginning of
EC2 and TM5. In addition, these phenylalanine residues are both conserved in human,
frog, and bony fish MC2Rs but distinct with all other melanocortin receptors (Figure 15).
Collectively, these observations indicated that position T164/V157, F168/F161, and
F178/F171 are involved in the interacting sites for MC2R to bind ACTH(1-24),
specifically on the KKRRP motif of this peptide.
In addition, majority of these significant residues were different between these
two receptors, reflecting that the tertiary structure of TM4/EC2/TM5 in these receptor
may interact with KKRRP motif in different ways. First, three significant hMC2R
residues (S169, H170 and L181) turned out to be unimportant for rtMC2R. Note that
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S169 and H170 together with F168 are the first three amino acids in hMC2R EC2. These
residues accounts for 33% of entire EC2, and 50% of significant residues identified in
hMC2R TM/EC2/TM5 domains. Hence, it appears that the extracellular loop 2 of
hMC2R plays a dominant role in terms of the function of this region. Second, newly
identified positions from rtMC2R that did not appear in hMC2R mutants were M158,
V159, K168, I172, and F175. Putting all 8 significant sites in rtMC2R together, there are
three successive positions in TM4, three relatively close positions in TM5, and two
discrete positions in EC2. 6 out of 8 positions are present in TM4 and TM5, suggesting
the predominant domains for rtMC2R interacting with ACTH(1-24) are TM4 and TM5
instead of EC2.
Based on the fold-change in the EC50 values of mutants as compared with wild
type MC2R, these sites were further sorted into three categories (As shown in Figure 28):
1) EC50 larger than 100-fold of wild type MC2R, including F178 of hMC2R, V159 and
F175 of rtMC2R (Positions labeled with *); 2) EC50 larger than 10-fold of wild type
MC2R, including H170 of hMC2R and F171 of rtMC2R (Positions labeled with °); and 3)
EC50 smaller than 10-fold of wild type MC2R. In this figure, 5 out of 14 residues caused
the EC50 values of mutants to increase 10-fold than the wild type control. Note that
position F178/F171 in TM5 was the only one position that is identical in these two
receptors, restating the importance of this phenylalanine residue. Meanwhile, nonconserved positions in these 5 residues are H170 in EC2 of hMC2R EC2, and V159 and
F175 in TM4 and TM5 of rtMC2R. Hence, in addition to the same phenylalanine at TM5,
hMC2R and rtMC2R actually use different domains, which are EC2 or TM4/TM5.
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In conclusion, the comparative analysis revealed that position T164/V157 in TM4,
F168/F161 in EC2, and F178/F171 in TM5 are responsible for the interaction of
ACTH(1-24) KKRRP motif, and the importance of these positions are consistent for
hMC2R and rtMC2R. However, these receptors have slightly different preference within
the overall interaction site. hMC2R uses EC2 as the predominant domain with three
successive significant residues, whereas rtMC2R mainly relies on its TM4 and TM5
regions.
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N-terminal
[---------TM1----------]
IC1
[---hMC2R MKHIINSYENINNTARNNSDCPRVVLPEEIFFTISIVGVLENLIVLLAVFKNKNLQAPMYFFICS
rMC2R M-------NDVSALPSNHTDCQVVKVPHLVFLVLGMVSLSENLLVVVAVVRNKNLHSPMYMFICS
-----TM2---------]
EC1
[----------TM3------------]
hMC2R LAISDMLGSLYKILENILIILRNMGYLKPRGSFETTADDIIDSLFVLSLLGSIFSLSVIAADRYI
rMC2R LATFNTISSLSKTWETLMMEFSDVGQLDSRGDSVRRVDDIIDALLCMSFIGCICSFLAIAVDRYV
IC2
[--------TM4---------]
EC2
[-------TM5-------hMC2R TIFHALRYHSIVTMRRTVVVLTVIWTFCTGTGITMVIFSHHVPTVITFTSLFPLMLVFILCLYVH
rMC2R TIFHALRYHNIMTTRRAAAALAGIWALCGVAGAVMVAFCDATVIKIFFIVLFLISLLLILFLYVH
-]
IC
[-----------TM6-----------]
EC3
hMC2R MFLLARSHTRKISTLP-----RANMKGAITLTILLGVFIFCWAPFVLHVLLMTFCPSNPYCACYM
rMC2R MFLLARSHARKIAALPGSAMPHRSLRGALTLTMLFGVFVVCWAPFFLHLLLLMVCVENPYCECYR
[-----------TM7-------]
C-terminal
hMC2R SLFQVNGMLIMCNAVIDPFIYAFRSPELRDAFKKMIFCSRYW
rMC2R SLFQLNLVLLMSHAVVDPAIYAFRSAELRNTFRKMLFCSDSPLCYKVKALFH

Figure 24. Human and rainbow trout MC2R sequence alignment. Positions shaded in
black indicate identical sites in these receptors. h: human; r: rainbow trout
(Oncorhynchus mykiss).
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A.

B.

Figure 25. ACTH(1-24) dose response curves of TM4 mutant rtMC2Rs in the presence
of zfMRAP1.
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A.

B.

C.

Figure 26. ACTH(1-24) dose response curves of EC2 mutant rtMC2Rs in the presence of
zfMRAP1.
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A.

B.

C.

Figure 27. A-B) ACTH(1-24) dose response curves of TM5 mutant rtMC2Rs in the
presence of zfMRAP1. C) rtMC2R 7A mutant ACTH(1-24) activation curve.
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Table 8. EC50 values of 19 mutant rtMC2R with single alanine substitution.
Domain

Alanine Substitution

EC50 ± SEM (10-11M)

P Values

WT

N/A

4.6 ± 0.7

N/A

TM4

V153
G155
V157
M158
V159

3.4 ± 0.46
14 ± 6.0
19 ± 5.9*
15 ± 3.4*
510 ± 124*

0.29
0.1
0.037
0.027
0.007

EC2

F161
C162
D163
T165
V166
I167
K168
I169

22 ± 7.3*
17 ± 6.4
1.7 ± 0.59
5.8 ± 2.1
5.6 ± 2.0
2.4 ± 1.1
8.2 ± 1.5*
1.5 ± 0.9

0.045
0.077
0.098
0.12
0.089
0.42
0.02
0.43

TM5

F170
F171
I172
V173
L174
F175

5.8 ± 0.52
214 ± 84*
26 ± 8.2*
3.9 ± 0.68
16 ± 5.6
460 ± 200*

0.1
0.03
0.027
0.19
0.081
0.043

Septuple
Mutation

V157, M158, V159,
F161, F171, I172, F175

N/A

(7A)

EC50 values are expressed as mean ± SEM (n=3). Statistical differences were assessed
by student t-test compared with ACTH(1-24) (*:P<0.05, **:P<0.005). N/A: No
activation. Position A154, A156, A160 and A164 were not tested.
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A.

B.
[----Mutant region---]
EC2
TM5
8
°
*
hMC2R RTVVVLTVIWTFCTGTGITMVIFSHHVPTVITFTSLFPLMLVFILCLYVHMF
rMC2R RAAAALAGIWALCGVAGAVMVAFCDATVIKIFFIVLFLISLLLILFLYVHMF
*
°
*
TM4

Figure 28. Positions (Red) that significantly affected ACTH signaling in human and
rainbow trout MC2R TM4, EC2 and TM5 domains. A) Fold increase of mutant EC50
values as compared with wild type MC2R. B) *: residues that had an EC50 over 100-fold
of wild type MC2R; °: residues that had an EC50 over 10-fold of wild type MC2R;
Positions shaded in gray indicate identical sites of these receptors. h: human; r: rainbow
trout (Oncorhynchus mykiss).
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CONCLUSION

The melanocortin-2 receptor has two functional activation features which are
distinct from the other melanocortin receptors (e.g., MC1R, MC3R, MC4R, MC5R):
MRAP1 dependency and ligand selectivity for ACTH (Hinkle and Sebag 2009; Webb
and Clark, 2010). These features of MC2R had appeared since the ancestral ray-finned
fishes diverged from ancestral cartilaginous fishes over 400 million years ago (Reinick et
al., 2011). This study focused on the important sites in both ACTH(1-24) and MC2R that
are responsible for receptor activation, and whether this pattern has changed between
mammal (human) and bony fish (rainbow trout) MC2Rs.
In the sequence of melanocortin peptides, the HFRW motif is required in order to
activate melanocortin receptors (Figure 2B). Previous studies on human MC4R identified
ten residues located in the TM2, TM3, TM6 and TM7 regions that are involved in the
binding of the HFRW motif (Pogozheva et al, 2005). In human MC1R, MC3R, MC4R
and MC5R 90% of these residues are identical, and as a result all of these receptors can
be activated by ACTH or any type of MSHs. In MC2Rs, 70% of these residues are
conserved in human, frog and rainbow trout MC2R orthologs as well (Figure 24). As a
result, the HFRW motif binding site for MC2R in human and rainbow trout should be at
the same positions (i.e., TM2, TM3, TM6, and TM7). Zone A analog stimulation results
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(see Chapter 1) indicated that the HFRW motif was critical for both hMC4R and MC2R
(human and rainbow trout) with a subtle difference predicted at the tertiary structure level
for the two receptors (Table 3 and Table 7). The tryptophan (W9) was the most important
position in the HFRW motif for the activation of both hMC2R and hMC4R, whereas in
rainbow trout MC2R, the arginine (R8) seems to be more important than tryptophan (W9).
In addition to the requirement for the HFRW motif, the KKRRP motif was also essential
for MC2R activation, especially with respect to the rainbow trout receptor (Table 7). In
addition, residues R17R18P19 are more important than K15K16in both hMC2R and rtMC2R
(table 3 and Table 7). Finally, the sequence between the HFRW motif and the KKRRP
motif is GKPVG. Replacement of individual residues of this region did not adversely
affect receptor activation of both hMC2R and rtMC2R. Nevertheless, this region should
be important, because incubation of receptor-transfected CHO cells with two peptides
each containing HFRW motif and KKRRP motif respectively (i.e., α-MSH and the
KKRRP analog), was unable to activate hMC2R (Figure 11B). This controversy was
resolved by testing two truncated analog ACTH(1-22) and ACTH(1-21) which were also
unable to activate hMC2R and rtMC2R as well (Table 3 and Table 7). Collectively, it is
now clear that the sequence of the HFRW motif and the KKRRP motif in ACTH(1-24)
can activate hMC2R and rtMC2R as a result of the sequence length in between these two
motifs (i.e., GKPVG) that properly orients the ligand to its binding sites in the receptor.
After conducting studies on the features of ACTH(1-24), this thesis then
addressed questions relating to the mechanism for activation of MC2R. Although both
HFRW and KKRRP motif are required in MC2R activation, they play different roles in
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the binding of ACTH(1-24) to MC2R. Schwyzer (1977) had proposed that the KKRRP
motif in ACTH played a critical role in the binding of the ligand to the receptor. As
indicated in Chapter 2, ACTH(15-24), the KKRRP motif analog, significantly reduced
ligand binding affinity, whereas analog A4, the HRFW motif analog, did not show any
effect on the binding curve (Table 3). Furthermore, a short peptide (KKRRPVKVYP)
only containing the last ten amino acid residues in ACTH(1-24) was able to bind to
hMC2R to the same degree as full length ACTH(1-24) (Figure 12D). These observations
led to the discovery of an ACTH(1-24) antagonist (KKRRPVKVYP) that specifically
targets hMC2R instead of other melanocortin receptors. In our in vitro system, the
application of this antagonist can block ACTH(1-24) activation completely at the
concentration of 100nM, and it can reduce ACTH(1-24) activation by 35% when applied
at concentration of 10nM (Figure 12C). These observations lend support to the
hypothesis presented in Figure 10 that ACTH first binds to MC2R at the KKRRP motif,
and then the HFRW motif in the ligand is positioned into HFRW binding site on the
receptor because of the “bridging” action of the GKPVG motif in the ligand.
The studies on the ACTH antagonist set the stage for the characterization of the
KKRRP binding site on the receptor (Chapter 3). The KKRRP binding site in MC2R
appears to be the predominant region that is not only defining its ligand selectivity, but
also initiating the binding of ACTH(1-24). The 3-dimensional model for MCRs (Figure
14) predicts that the transmembrane domains for HFRW binding site (TM2, TM3, TM6
and TM7) are at close proximity and form the space to allow HFRW motif to sit inside.
Based on that orientation, it would follow that the KKRRP motif of ACTH should be
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positioned within the region close to TM4, TM5 and EC2 (Figure 14). In order to test this
hypothesis, we made single-alanine mutant receptors at this region in both human and
rainbow trout. Although the sequence identity between hMC2R and rtMC2R for this
region is only 32% (Figure 28), the importance of certain positions in TM4, EC2, and
TM5 for the activation of receptor became apparent. It appears that TM5 was important
for both receptors (F178 hMC2R/F171 F175 rtMC2R), whereas EC2 (H170) of hMC2R
and TM4 (V159) of rtMC2R were also involved in receptor activation (Figure 28). Of all
the residues in this region that adversely affected the EC50 by a factor of 5 fold or greater,
only F178 in hMC2R and F175 in rtMC2R are at the same relative position in their
respective receptor. Clearly the 3-dimensional structure of this binding pocket must be
the feature that human receptor and the rainbow trout receptor share in common.
In the next step in this research it would be informative to use ACTH(15-24)
to probe the proposed KKRRP binding site. For these experiments, the iodinated
competitive inhibitor (KKRRPVKVYP) would be made in order to support the
conclusion that these sites in MC2R are involved in the binding of KKRRP motif of
ACTH. When applied to the mutant receptors, the prediction would be that the
competitive inhibitor should cause a decline in the binding curves as compared to the
wild-type receptor. Furthermore, 3D structure modeling analysis of MC2R should be
done in the future to obtain the detailed description of receptor/ligand relationship.
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